
==== Front
J Physiol Sci
J Physiol Sci
The Journal of Physiological Sciences : JPS
1880-6546
1880-6562
BioMed Central London

39313800
933
10.1186/s12576-024-00933-4
Review
Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders
http://orcid.org/0000-0002-5418-2191
Lasheen Noha N. nohalasheen@gu.edu.eg

12
http://orcid.org/0009-0005-2749-8982
Allam Salma 3
http://orcid.org/0009-0007-0717-9225
Elgarawany Abdullrahman 3
http://orcid.org/0009-0004-1124-8084
Aswa Darin W. 3
http://orcid.org/0009-0003-8820-5480
Mansour Rana 3
http://orcid.org/0009-0003-6402-0625
Farouk Ziad 3
1 https://ror.org/04x3ne739 Department of Basic Medical Sciences, Faculty of Medicine, Galala University, Suez, Egypt
2 https://ror.org/00cb9w016 grid.7269.a 0000 0004 0621 1570 Department of Physiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
3 https://ror.org/04x3ne739 Faculty of Medicine, Galala University, Galala City, Suez Egypt
23 9 2024
23 9 2024
2024
74 4616 2 2024
13 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Neurological disorders such as Alzheimer’s disease (AD), and Parkinson’s disease (PD) have no disease-modifying treatments, resulting in a global dementia crisis that affects more than 50 million people. Amyloid-beta (Aβ), tau, and alpha-synuclein (α-Syn) are three crucial proteins that are involved in the pathogenesis of these age-related neurodegenerative diseases. Only a few approved AD medications have been used in the clinic up to this point, and their results are only partial symptomatic alleviation for AD patients and cannot stop the progression of AD. Immunotherapies have attracted considerable interest as they target certain protein strains and conformations as well as promote clearance. Immunotherapies also have the potential to be neuroprotective: as they limit synaptic damage and spread of neuroinflammation by neutralizing extracellular protein aggregates. Lately, disease-modifying therapies (DMTs) that can alter the pathophysiology that underlies AD with anti-Aβ monoclonal antibodies (MAbs) (e.g., aducanumab, lecanemab, gantenerumab, donanemab, solanezumab, crenezumab, tilavonemab). Similarly, in Parkinson's disease (PD), DMTs utilizing anti-αSyn (MAbs) (e.g., prasinezumab, cinpanemab,) are progressively being developed and evaluated in clinical trials. These therapies are based on the hypothesis that both AD and PD may involve systemic impairments in cell-dependent clearance mechanisms of amyloid-beta (Aβ) and alpha-synuclein (αSyn), respectively, meaning the body's overall inability to effectively remove Aβ and αSyn due to malfunctioning cellular mechanisms. In this review we will provide possible evidence behind the use of immunotherapy with MAbs in AD and PD and highlight the recent clinical development landscape of anti-Aβ (MAbs) and anti-αSyn (MAbs) from these clinical trials in order to better investigate the therapeutic possibilities and adverse effects of these anti-Aβ and anti-αSyn MAbs on AD and PD.

Keywords

Immune checkpoint
Age-related neurodegenerative disorders
Alzheimer's disease
Parkinson's disease
Monoclonal antibodies
Galala UniversityOpen access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

issue-copyright-statement© The Physiological Society of Japan 2024
==== Body
pmcIntroduction

Aging is a progressive degenerative process that can be physiological and pathological [1–3] (Fig. 1). The physiological process of aging is triggered by a variety of biological and genetic processes, including telomere attrition [4, 5], DNA damage [6, 7], mitochondrial dysfunction [8, 9], reduced levels of nicotinamide adenine dinucleotide (NAD +) [10, 11], impaired macro-autophagy [12, 13], stem cell exhaustion [14, 15], inflammation [14, 15], protein imbalance [16], deregulated nutrient-sensing [17], altered intercellular communication [18–20] and dysbiosis [21, 22]. These changes collectively contribute to a decline in systemic function which are highly correlated with lifespan and incidence of all age-related diseases as shown (Fig. 1). In an aging world where people who are older than 65 are estimated to account for 20% of the population in 30 years. within that time range, it is predicted that the prevalence of neurodegenerative disorders related to age such as Alzheimer's disease (AD), Parkinson's disease (PD), frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), and vascular dementia (VCID) will triple [23, 24]. There are currently few, if any, disease-modifying treatments (DMTs) available for these disorders, making dementia one of society's most burdensome conditions [25]. Abnormally folded protein aggregates gradually accumulate in neurodegenerative conditions of elderly population, such as AD, PD, and FTD, they interfere with network function leading to the eventual loss of certain neuronal networks [26, 27].Fig. 1 Drivers of aging and age-related diseases include several key physiological changes such as NAD + depletion, telomere shortening, mitochondrial dysfunction, stem cell exhaustion, impaired macro-autophagy, DNA damage, protein imbalance, inflammation, dysbiosis, deregulated nutrient sensing, and disrupted cellular communication. These aging-related features are fundamental, antagonistic, and interconnected, collectively promoting the aging process as aging progresses beyond a certain point, organ and tissue functions decline, leading to a higher incidence and mortality of neurodegenerative disorders related to age such as Alzheimer's disease (AD), Parkinson's disease (PD), frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), and vascular dementia (VCID)

The literature search for this topic was performed using the PubMed, Embase, and Cochrane databases. The search followed a systematic approach and included articles from the inception of each database up to December 2023. Key search terms used were "aging", "neurodegenerative diseases", "Alzheimer's disease", "Parkinson's disease", "dementia", and "protein aggregates".

Pathogenesis of Alzheimer’s disease

Alzheimer’s disease (AD), a serious age-related neurodegenerative condition, is the major reason for senile dementia [28]. Characterized by gradual cognitive decline, memory loss, language problems, and behavioral disturbances [29]. The etiology of Alzheimer’s disease has been the subject of numerous theories over the years for better understanding of the disease renowned hypotheses that explain the underlying pathogenic processes and may have an influence on therapeutic possibilities are the tau hypothesis and the amyloid deposition hypothesis [30]. The amyloid hypothesis depends on the aggregation of extracellular senile plaques containing misfolded amyloid-beta peptide (Aβ) [31, 32]. These plaques mediate inflammation and interfere with nerve signaling, which ultimately results in escalating the disease. In the brains of patients of AD and in animal models, local inflammatory reactions and uncontrolled astrocyte reactivity have been seen, and they are thought to be important contributors in the development and escalation of the condition. Nonetheless, they are not the main causes [33, 34]. On the other hand, the tau hypothesis indicates that tau protein is essential for preserving microtubules, which are critical for neuronal structure and function. Excessive phosphorylation of tau in AD causes it to separate from microtubules and form neurofibrillary tangles. This can affect axon transport and neuronal function, resulting in cognitive impairment in AD patients [30]. Numerous attempts to prevent the progression of the disease have been made throughout the years as a result of the excessive accumulation of misfolded proteins and neuroinflammation. Targeting misfolded proteins have been used in these attempts to decrease the plaque load [35, 36]. Or administrating systemic anti-inflammatory drugs to decrease brain inflammation. However, inconsistent and contradictory findings have been made, and no drug has yet to demonstrate effectiveness in restoring or limiting patients cognitive decline [37–43].

Pathogenesis of Parkinson’s disease

PD is the second most prevalent neurodegenerative disease affecting old people, following Alzheimer’s [44, 45]. The incidence of Parkinsonism increases in the elderly, affecting populations over the age of 65 [46]. The motor symptoms of PD, such as tremors, bradykinesia, rigidity, as well as difficulties with walking and gait, are thought to be the outcome of pathological processes accumulation that exceed the ability of the brain to withstand or adapt to negative repercussions. It is becoming clear that the motor manifestations of PD could not appear for years have passed with continuing neurodegenerative cell death in the substantia nigra [47, 48].

The aggregation of alpha-synuclein protein (-syn) within neurons, which is coded by mutations in the -synuclein gene (SNCA), and the death of dopaminergic neurons in the substantia nigra are the hallmark features of PD [49, 50]. Later studies discovered that (α-syn) is apparent within Lewy bodies [51], which are intracellular protein aggregates primarily composed of (α-syn), neurofilament, and ubiquitin. The appearance of Lewy bodies in nerve cells is a hallmark of the pathology of PD [52] and is related to dopaminergic neuron death and activated microglia [53, 54]. In fact, (α-syn) can induce microglial activation and morphological changes [55].

The role of microglia in the neurodegenerative disorder

There is evidence from pathology, genetics, and mouse studies that resident immune cells in the cerebrospinal nervous system play a significant function in disease advancement in both AD and PD. A variety of tissues have their own specialized, resident macrophages that perform both general innate immune performs and tissue-specific functions [56]. Microglia, the resident immune cells of the cerebrospinal nervous system, were previously a topic of much debate, but it is now accepted that they detect and respond to nearby pathogens. Microglia regularly survey their milieu, counter injury, and infectious agent, and contribute to tissue healing [57–59]. They also interact closely with nerve cells and can affect nerve cell function, because they are involved in formation of neurons de novo and synaptic pruning [57, 59, 60].

In a study, researchers noticed a subset of microglia with fragmented branches and beading in their process, which they termed dystrophic microglia [61, 62]. The number of dystrophic microglia was found to be higher in individuals with AD, DLB, or limbic predominant age-related TDP-43 encephalopathy compared to age-matched controls [63]. It is suggested that microglia with dystrophic morphology are senescent microglia [61]. When compared to activated microglia, senescent microglia are believed to have lower migration and phagocytic capabilities when compared to activated microglia [64].

Current treatments for age-related neurodegenerative disorders

Numerous alternative therapies for age-related neurodegenerative disorders, including Alzheimer’s disease (AD) and Parkinson’s disease (PD), are presently under consideration and investigation. Stem cell therapy, gene therapy, and anti-aging drugs like metformin, rapamycin, resveratrol, and senolytics are some of those therapies.

Stem cell therapy

The capacity to regenerate and differentiate into mature cells is what distinguishes stem cells from other types of cells. Exogenous stem cell implantation and stimulation/boost of endogenous brain progenitor cells are the two therapeutic approaches that use stem cells. Replacing damaged and lost cells directly, acceleration of tissue healing, growth molecules and trophic factors generation, immunomodulation and mobilization of endogenous stem cells, are a few potential methods of stem cell therapies. Engrafted stem cells have been shown to integrate into the local neuronal and synaptic networks to enable neurological regeneration in animal models of neurodegeneration [65–69].

Stem cell therapies for Alzheimer’s disease

Mesenchymal stem cells (MSCs) start the remyelination, immunological balancing, and brain regeneration processes. Additionally, amyloidogenesis and/or microglial activation can be affected by MSCs by reducing the accumulation of amyloid-beta-peptide (Aβ) and promoting cognitive recovery. Adipose tissue-derived mesenchymal stem cells (AD-MSCs) can alleviate memory deficits by raising levels of IL-10 and vascular endothelial growth factor, regulating microglial activation in the brain, and lowering levels of amyloid plaques and Aβ in AD animal models [65, 70, 71].

Stem cell therapy for Parkinson’s disease

Parkinson’s disease dementia (PDD) is characterized by cognitive impairment and the presence of α-synuclein. There is not much research assessing the effectiveness of transplantation of stem cells in treating PDD’s cognitive impairment, despite some reports suggesting that dopaminergic precursor transplantation reduced PD’s motor symptoms. Α-synuclein aggregates are regarded as harmful and cause neuronal deaths in various α-synucleinopathies. They are released by neurons through the process of exocytosis, which are subsequently absorbed by neuroglia and neuronal cells through the process of endocytosis. Additionally, it is hypothesized that Alpha-synuclein and N-methyl-d-aspartate (NMDA) receptor interaction may promote clathrin-dependent endocytosis of NMDA receptors [72–74].

Gene therapy

Gene therapy consists of implanting a healthy gene into the genome to substitute for a damaged gene that causes a specific disorder. To implant the gene, a carrier which is known as a “vector” is used, the carrier must be very targeted and show efficiency in releasing one or more genes. That are the right sizes for clinical applications, not being acknowledged by the immunity, and are purified at high concentrations. Once the carrier has been inserted, it should not aggravate the immune system by causing any allergic or inflammatory reactions. It must improve regular functions, remedy deficiencies, and stop harmful activity. The inclusion of viral genetic material in the plasmid is a major aggravating factor, as it may trigger an immediate immune response in addition to a potential neoplastic transformation. There are currently two main methods for altering a cell’s genetic makeup: virus-mediated and by physical mechanisms using preparations made using advanced nanotechnology techniques [75–77].

Gene therapy for Alzheimer’s disease

One strategy to lessen the pathogenesis of AD is to target Aβ. Zhang et al. produced a recombinant adeno-associated virus (AAV) that expressed the fusion protein CB-Abeta42 (cholera toxin B subunit and A42), which was one of the initial attempts. PDAPPV7171 transgenic mice developed large amounts of anti-A-42 antibodies after receiving a single intranasal, intramuscular, or oral dose of the AAV-CB-A-42 vaccine. High levels of anti-Aβ42 antibodies significantly decreased the amount of Aβ in the brain, reduced plaque-associated astrocytosis, and enhanced memory and cognitive performance [78, 79].

Gene therapy for Parkinson’s disease

There have been found a number of potential genetic targets for the treatment of PD. Disease-modifying and non-disease-modifying targets fall under this category. In order to alleviate Parkinson’s manifestations, non-disease modifying therapies aspire to promote normalizing defective basal ganglia firing by expressing either dopaminergic or GABAgenic enzymes. These therapies have no effect on the fundamental pathophysiological process; they merely treat the symptoms. Treatment plans concentrate on avoiding PD-mediated cell death and/or rebuilding destroyed neurons to combat the disease. Nigral overexpression of growth factors has been proven to have neuroprotective qualities [80, 81].

Anti-aging drugs

The physiological process of aging in the human body is irreversible, and the changes brought on by aging that accompany this process also have a role in several neurodegenerative diseases, such as AD and PD. Aging has become a major risk factor for most neurodegenerative diseases, which increases morbidity and death in elderly individuals. Anti-aging drugs including resveratrol, rapamycin, metformin, and senolytics (Table 1) are focused on the key ageing traits that affect autophagy and inflammation [82]. Table 1 Anti-aging drugs and their adverse effects

Drugs	Original use	Adverse effects	
Metformin	Anti-diabetic	In people over 65, long-term metformin use raised the incidence of AD. It has been demonstrated that the reduction of mitochondrial respiration by metformin aids in the onset of PD. In a population-based study, it was discovered that it increased the rate of AD and decreased cognitive function in diabetic patients. In a cell culture model, it was discovered to increase the formation of Aβ, and the most common side effects in those who take it are diarrhea, nausea, flatulence, indigestion, vomiting, and abdominal discomfort. Metformin use for a long time caused a vitamin B12 deficit [83]	
Rapamycin	Immunosuppressant, anticancer	Hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, glucose intolerance, insulin resistance, new-onset diabetes, anemia, thrombocytopenia, dermatological events, gastrointestinal disorders, sinusitis, respiratory, urinary infections, and testicular dysfunction [84]	
Resveratrol (RE)	Anti-inflammatory, antioxidant, anti-platelet, anti-hyperlipidaemic, immune-modulator, anti-carcinogenic, cardioprotective, vasorelaxant, and neuroprotective effects [85]	White blood count (WBC), IL-6, tumor necrosis factor (TNF) levels, and alanine aminotransferase (ALT) levels, can all be severely impacted. High doses of RE might cause nausea, mild to moderate diarrhea, anal pruritis, and allergic reactions [85]	
Senolytics	Anti-cancer drugs	Aging pancreatic beta cells have demonstrated enhanced release of insulin, and elimination of these cells may as a result induce an imbalance in the homeostasis of glucose. Additionally, animals treated with navitoclax showed cytotoxicity targeting bone marrow precursor cells and osteoblasts [86]	

Novel approaches to the treatment of age-related neurodegenerative disorders

In order to regulate the immune response and promote self-tolerance, immunological checkpoints such as the regulatory molecules programmed cell death protein-1 (PD-1) and its ligands are fundamental. There are two identified ligands for PD-1: PD-L1 (additionally known as B7 homolog 1, B7-H1) and PD-L2 (or B7-DC) [87]. When triggered by PD-L1 and PD-L2, PD-1 inhibits T cell activity. Adaptive and innate immune cells, mesenchymal cells, and cancer cells are just a few of the cell types for which PD-L1 expression can be induced. The PD-L2 protein, on the other hand, is only produced by a very restricted subset of tumor cell types and antigen-presenting cells (APCs) [88]. T cell exhaustion, a potentially persistent state of malfunction, is caused by PD-1 and PD-L1 interaction. Tumor cells take advantage of this interaction to escape immunosurveillance. Immune checkpoint inhibitors (ICIs) have become a crucial component of cancer treatment [89], including melanoma, non-small-cell lung cancer (NSCLC), small cell lung cancer (SCLC), primary mediastinal large B-cell lymphoma (PMLBCL), classical Hodgkin lymphoma (cHL), head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), bladder cancer, Merkel cell carcinoma (MCC), and microsatellite instability high (MSI-H) or DNA mismatch repair deficient (dMMR) adult and pediatric solid tumors [90]. The host immune system is induced by immune checkpoint inhibitors to fight cancer cells [91, 92]. By boosting chemokine-dependent immune cell infiltration into the malignant disease zone and stimulating IFN-γ at the tumor tissue, blocking the PD-1 pathway could enhance fighting chances against cancer [93, 94]. By inhibiting the production of glycolysis-related enzymes, stifling glucose absorption, and lowering AKT phosphorylation, anti-PD-L1 antibodies can have a detrimental effect on cancer cell metabolism [95, 96]. Therefore, new and innovative approaches to treating neuroinflammation are therefore made possible by immunotherapy and immune checkpoint blockade.

The general role of PD-1 and PD-L1 in immune system

A healthy immune response is essential for bodily protection while avoiding host injury. T lymphocytes stimulation needs two indications, as is widely known. The initial signal is produced as a result of the interplay of the T lymphocyte receptor (TCR) in hand with its corresponding antigen, which is introduced by molecules of MHC generated by antigen-presenting cells (APCs). The engagement of receptors that are responsible for co-signaling on T lymphocytes with declared ligands on APCs provides the second signal. Those molecules of co-signaling may induce both suppressing and stimulating stimuli, therefore the balance of these signals determines the fate of T cell activation. The system of pathways that include co-signaling permits the body’s immune system to fine-tune immunological response control. PD-1 (sometimes referred to as CD279) is a receptor that causes cell death. major receptor of coinhabiting on surface of the CD28 family that inhibits T and B lymphocytes induction via interactions with its PD-L1 (which is additionally recognized as CD274 or B7-H1) and PD-L2 (also known as CD273 or B7-DC) ligands [97–101]. PD-1 is critical in the regulation of T lymphocytes exhaustion and induction. Extreme activation of antigen of T lymphocytes, as in infection chronically or cancers, promotes CD8 and CD4 T lymphocyte fatigue, which is featured by losing T lymphocyte effective abilities such as influenced growth, suppressed cytotoxicity and expression of transcription factor as shown (Fig. 2) [102, 103]. PD-1 ligation shall also limit the formation of effector T cells by switching through glycolysis regarding ß-oxidation of fatty acid, the me

tabolic makeup of excited T lymphocytes [104]. Few studies found the fact that the interplay of PD-1, PDL-1 and PDL-2 modulates peripheral CD8 and CD4 T lymphocyte resistance immunologically by attenuating self-reactive T lymphocyte reaction during self-antigen presentation by dendritic cell (DC) [105, 106]. Also, some studies have found interesting that the two PD-L1 along with PD-1 are strongly displayed on regulatory T lymphocytes [107, 108]. On the other hand, effective T lymphocytes, where the signaling of PD-1 limits growth, PD-1 stimulation manages Treg lymphocyte growth, maintenance, and function [108]. PD-1 as well as PD-L1 are both substantially expressed on Treg cells, according to other studies. Unlike effective T lymphocytes, where PD-1 alerting reduces multiplication, PD-1 stimulation regulates a developing effect. Treg lymphocyte regulates a sustaining effect and abilities, for instance, PD-L1 transformed mice naive T lymphocytes carrying CD4 to regulatory T lymphocytes by inhibiting the Akt/mTOR and ERK2 cascades while simultaneously increasing the phosphatase and tensin homolog (PTEN) [109–113]. According to two studies, the interplay between PD-1 and its ligands modulates T lymphocyte tolerance with the peripheral CD4 and CD8. Self-reactive T cell response is reduced when DC presents self-antigen. Surprisingly, PD-1and PD-L1 axis are important in modifying regulatory T (Treg) cell development and function. FoxP3 expression in inducible Treg cells requires signaling by PD-L1 shown on DCs in spleen. DCs lacking PD-L1 had a significantly reduced ability to convert naive antigen-specific T lymphocytes having CD4 receptors into regulatory T lymphocytes in vitro [114]. In addition, traditional polarized Th1 human T lymphocytes displaying PD-L1 that were turned into regulatory T lymphocytes with tolerance, showing a decrease in Tbet, an increase in the production of IFNs, and a rise in the conveying of FoxP3. By this scenario, PD-L1-dependent Th1-to-regolatory T lymphocytes division was caused by decreased Th1 lymphocytes STAT stimulation via the route of SHP1 and 2 communications, which is downregulation of the receptor of PD-1 [115]. It has lately been demonstrated that the signals to PD-1 preserve equilibrium of Foxp3 in regulatory inducible T lymphocytes by blocking asparaginyl endopeptidase (AEP), an endolysosomal protease that immediately breaks Foxp3 in those lymphocytes [116].Fig. 2 Understanding T lymphocyte stimulation and the PD-1/PD-L1 pathway: the pathway of programmed cell death (PD) and cytotoxic T lymphocyte antigen-4 (CTLA-4) plays a crucial role in the suppression of T-cell activation. T-cell activation is stimulated by the interaction between the major histocompatibility complex (MHC) and the T-cell receptor (TCR), along with the co-stimulatory interaction between B7-1/2 and CD28. In contrast, CTLA-4 binds to B7-1/2 and delivers an inhibitory signal to prevent T-cell activation. Within the PD pathway, there are interacting molecules: PD-1, PD-L1, PD-L2, and B7-1 (CD80). PD-L1 and PD-L2 are ligands for PD-1, and their binding to PD-1 results in the suppression of T-cell activation. Additionally, PD-L1 interacts with B7-1 (CD80) on activated T cells to inhibit their activity

The potential role of PD1/ PDL1 as “immune regulators”

PD1/PDL1’s proposed function as “immune regulators”. PD-1 is an essential immunosuppressive molecule that may regulate T-cell effector activities in a variety of ways. It has been extensively demonstrated that PD-1 receptor signaling suppresses TCR-mediated cell activation (for instance, division and cytokine synthesis) [117–119]. Nevertheless, recent research indicates that the PD-1 axis is also essential for managing T-cell activation throughout various neuroinflammatory disease models. Mair and al. examined a role of PD-1 within both the growth and preservation of T-cell flexible tolerance [for example, once antigen activation proceeds in vivo, T cells enhance a hyporesponsive state [120]. After being in an EAE approach, participants were exposed to substantial quantities of autoantigens. That study discovered that the presence of PD-1 is higher on adaptive T cells with their CD4 receptors in the CNS. However, PD1 removal did not hinder T cells are prevented from forming an adjusted phenotype in living cells as well as in laboratory, thus PD-1 is not essential for T cells to keep being nonresponsive in EAE [120]. This data indicates that PD-l is not required for that process, the contradiction of most earlier data on PD-1 participation in T-cell adjustment [121]. It was revealed utilizing an identical disease model for animals (EAE) that T lymphocytes with their CD4 accessing the CNS throughout the pinnacle of sickness stimulate PD-1, and that increase is linked to a decrease in Th1 cells as a result of PD L1 + microglia producing nitric oxide. These findings support PD-1’s function in EAE control by suppressing transformation of Th1 cells [122]. The reduction of T-cell with CD8 receptors activity observed in rats with SCI was linked to the activation regulating processes, consisting of overexpression of PD-1 along with PD-L1. Wounded rats showed a greater quantity of PD-1 and T-cell with CD8 receptors, in addition to a greater surface transcription of this receptor. The overproduction of PD-1 ceases the immune-inflammatory process and prevents inflammation from spreading at the site of harm [123]. Myeloid-like cells are called microglial cells. Live in the CNS and are highly reactive to variations in brain homeostasis. During autoimmune inflammation, microglial cells act as the point of contact involving the body’s immune system and the CNS [62]. In healthy mice, microglial cells produce PD-L1 at low levels (about 20%), yet after 1 week of viral brain infection, the expression level could rise to more than 90% [124]. In the course of neuroinflammation, both microglia and astrocytes boost PD-L1 in combination with MHC I and MHC II, indicating that indigenous glial cells have a role in reducing CNS illness [125]. Furthermore, adoptive transfer of PD-L1-expressing M2-polarized microglia decreased. The seriousness of an existing EAE, underlining the significance of PD-L1’s regulation in neuroinflammation [126]. However, using the PD-L1 recombinant protein construct to activate PD-1/PD-L1 signaling significantly decreased inflammatory responses and cerebral edema following SBI. Therefore, in SBI, the PD-1 as well as PD-L1 signaling mechanism shall be implicated as part of a “self-protection function” [127]. The most prevalent is Alzheimer’s disease, a kind of dementia in humans distinguished by symptoms such as mental impairment as well as neuronal degeneration. AD diseases are distinguished because of two circumstances: extracellular amyloid plaques (A) in addition to neurofibrillary tangles that contain (Tau) intracellularly [128]. The biological process behind TAU protein and amyloid buildup is unclear, as well as the system’s defenses might be involved in the development of pathogens [129]. According to recent studies, systemic immunity ought to be enhanced instead of being stifled in order to aid brain recovery via an immune-dependent reaction. The PD-1 route has been hypothesized in this regard. A viable Alzheimer’s disease targeted treatment [130]. The transfer of blood-borne myeloid-like cells (monocyte that are derived from macrophages) to the CNS is currently proven in Alzheimer’s disease rat models to be beneficial neurologically. PD-1 on T lymphocytes, as well as PD-L1 on monocytes and macrophages, are considerably lower in AD patients and persons with moderate memory impairment when compared with time and gender-matched healthy controls [131]. The PD-1/PD-L1 axis represents a prospective target for AD therapy using antibodies.

The potential of PD-1/PD-L1 ICIs combination therapy in treating Alzheimer’s disease with muramyl dipeptide

A synthetic immunoreactive peptide called muramyl dipeptide (MDP) is composed of N-acetyl muramic acid and a short amino acid chain of l-Ala-d-isoGln that was detected by the human innate immune system, which is a cytoplasmic receptor called nucleotide-binding oligomerization domain 2 (NOD2). It can activate the immune system by increasing the production of IFN-γ and other cytokines, promoting the differentiation and proliferation of a specialized group of the WBCs called lymphocytes which are crucial for the immune system’s defense against foreign bodies. Additionally, it may be used for increasing the potency of vaccines and drugs as an effective adjuvant [132, 133]. MDP can produced synthetically despite it being naturally derived from Gram-negative and Gram-positive bacteria cell walls [134]. The modulation of the innate cells of the immune system, such as the local patrolling monocytes and microglia, has been studied recently in relation to the NOD2 receptor ligand MDP. Preclinical results show that MDP injections can delay cognitive decline and protect female and male mice’s blood–brain barrier (BBB) by different mechanisms as presented in Fig. 3. For example, the findings in male mice support the idea that the MDP activates the BBB’s sink effect, reducing the brain’s accumulation of amyloid. Based on osmotic principles, this hypothesis states that amyloid is in balance with blood vessels and the brain, and the objective is to eliminate amyloid from the periphery and expel it from the brain. MDP appears to have a more limited beneficial effect on female brains because microglia encircle amyloid plaques and prevent amyloid peptides from spreading [135]. Accordingly, investigations have shown that monocyte populations can do this by removing amyloid plaques and producing growth factors and anti-inflammatory compounds, which causes the sink effect [136]. Simultaneously, an integrated approach that combines modulation of NOD2 and PD-1 could yield superior outcomes, according to recent evidence. This approach provides the transformation of inflammatory monocytes into patrolling monocytes. The promise of these therapeutic interventions is being understood by pharmaceutical entities who are currently conducting preclinical research on them. In summary, there is strong evidence suggesting that MDP has the potential to be a catalyst for this monocyte discussion, and the PD-1 inhibitor could trigger the patrolling monocytes in the brain [137].Fig. 3 The well-known strain APPswe/PS1 was administered chronically with MDP once a week for three months. The findings show how a NOD2 agonist triggers the transformation of inflammatory monocytes into patrolling monocytes. The toxic vascular Aβ is then enveloped as these cells patrol the arterial network to remove it from the brain. MDP aids in the removal of Aβ from the brain and into the blood, where it might be collected by blood monocytes that are on the lookout, by activating LRP-1 transporters [91, 94]

PD1/PDl-1 from experimental to clinical investigation

Immunotherapy focuses on reducing the damaging impact of protein accumulation such as Aβ and αSyn accumulation by removing and neutralizing toxic species. Results from the first immunization experiment against Aβ demonstrate that a small number of meningoencephalitis patients that changed the vaccine’s formulation led to a change in the field of immunotherapy from active to passive immunization. The field has recently advanced to target other proteins in AD, specifically “Syn than Aβ” [138].

MAbs in neurodegenerative disorder

Monoclonal antibodies (mAbs) are synthetic molecules designed to act as mimic antibodies, capable of either replenishing, improving, or replicating the immune system's assault on cells. These antibodies are monospecific, showing that they are identical and originate from a single type of immune cell, all of which are clones of a different parent cell [139]. There are multiple categories of mAbs. Firstly, there are naked mAbs, which operate independently without any attached drugs or radioactive substances. Secondly, there are conjugated mAbs, which are linked to chemotherapy drugs or radioactive particles to directly administer these treatments to specific cells. Lastly, there are bispecific mAbs, which are designed to bind to two different antigens simultaneously, thereby enhancing their capacity to bring together target cells and immune cells [140, 141]. Monoclonal antibodies (mAbs) are under investigation in neurodegenerative disorders like Alzheimer's and Parkinson's disease for their potential to target and neutralize pathogenic proteins that contribute to disease progression. In the case of AD, mAbs such as aducanumab are used to specifically target Aβ plaques. The goal is to decrease the accumulation of these plaques and maybe slow down the decline in cognitive function [142]. In the case of Parkinson's disease, researchers are studying the use of monoclonal antibodies to specifically target alpha-synuclein, a protein that forms damaging aggregates in the brains of people with the condition [143]. Multiple clinical trials have been carried out to assess the effectiveness and safety of these drugs. The FDA controversially approved aducanumab based on the evaluation of its effectiveness in Alzheimer's patients during the EMERGE and ENGAGE trials [144]. Ongoing trials in Parkinson's disease are investigating the use of antibodies, including prasinezumab. Early results indicate that these antibodies have the potential to slow down the progression of the disease [143].

Aducanumab in Alzheimer’s disease

Aducanumab, also known as Aduhelm®, is a monoclonal antibody specifically developed for the treatment of AD. The mechanism of action involves specifically targeting amyloid-beta plaques, which are a characteristic feature of this disease. Aducanumab has the ability to bind to clustered amyloid-beta and facilitate its elimination from the brain, which could delay the advancement of the disease. Clinical studies had various results, but the FDA's approval in 2021 via fast track was significant. Discussion developed due to concerns regarding the decision's efficacy and the need for further validation of clinical benefits. Aducanumab represents a significant advancement in the treatment of AD, effectively targeting a crucial pathology associated with this fatal neurodegenerative condition. The safety and effectiveness of aducanumab in AD patients were evaluated in two significant Phase 3 clinical trials called ENGAGE and EMERGE. To assess the efficacy of aducanumab in reducing amyloid-beta plaques and potentially slowing down cognitive decline, these trials enrolled individuals diagnosed with early-stage AD. The EMERGE trial yielded encouraging results, demonstrating a significant reduction in amyloid-beta plaques and interesting implications for cognitive and functional outcomes in clinical settings. The ENGAGE experiment has been discontinued due to a lack of comparable favorable outcomes. Despite the inconsistent results from the two trials, the evidence provided by EMERGE was sufficient to justify aducanumab's application for approval by the FDA based on its effectiveness. The trials underscored the challenges in developing efficacious therapies for AD and the intricate and diverse nature of treatment results [144, 145] (Table 2).Table 2 Some clinical trials of aducanumab in Alzheimer’s disease

Drug	Target	Mechanism of action	Clinical Trial.gov	Phase	Intervention	Status	Refs.	
Aducanumab	Aβ	Target and bind to Aβ plaques in the brain. Then facilitates clearance of Aβ through activation of the immune system, specifically microglia, which phagocytose the antibody-bound Aβ aggregates	NCT05216887	Phase 1	Aducanumab single IV weight-based dose on day 1 or two fixed SC injections on day 1 and 15	Active, not recruiting	[146]	
ENGAGE, NCT02477800a, 221AD301, 2015–000966-72	Phase 3	Monthly IV infusions of aducanumab (low or high dose) or placebo	Terminated (study was discontinued based on futility analysis done and not based on safety concerns. Follow-up visits and closing out study activities are completed)	[144, 147]	
EMERGE, NCT02484547a, 221AD302, 2015–000967-15	[144, 147]	
ENVISION phase IV confirmatory trial, NCT05310071a	Phase 4	Monthly IV infusion of aducanumab up to 10 mg/ kg or placebo	Recruiting	[148, 149]	
EMBARK, NCT04241068a, 221AD304, 2019–004368-22	Phase 3	10 mg/kg of aducanumab by IV infusion every 4 weeks for a total duration of 100 weeks	Active, not recruiting	[150]	

Lecanemab in Alzheimer’s disease

In january 2023, lecanemab (Leqembi®) (also known as BAN2401) is approved by the FDA for the treatment of AD to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild AD dementia) with confirmed brain amyloid pathology. It is a monoclonal antibody that targets Aβ aggregates implicated in AD pathology. Derived from a blood lymphocyte library of elderly individuals without cognitive impairment, Lecanemab specifically binds to protofibrils and oligomers of Aβ, potentially reducing their toxic effects on neurons and slowing disease progression. The clinical development of Lecanemab has shown promise, with early trials suggesting it may help reduce Aβ plaques and possibly alleviate cognitive decline in Alzheimer's patients [151]. In a double-blind, phase 3 trial, compared to placebo, lecanemab significantly reduced brain amyloid levels and moderately slowed cognitive and functional decline in early AD over 18 months (Clarity AD ClinicalTrials.gov number, NCT03887455; funded by Eisai and Biogen). The work brought attention to the fact that Lecanemab is very selective for harmful amyloid species. The lecanemab group did have a higher incidence of adverse events, but these were often moderate and asymptomatic, especially ARIAs (amyloid-related imaging abnormalities) [151, 152].

Other MAbs used in Alzheimer’s disease

Additional monoclonal antibodies used in the treatment of AD include gantenerumab, donanemab, solanezumab, crenezumab, and tilavonemab. Each of these antibodies serves specific functions in addressing the pathophysiology of the illness, accompanied by certain adverse effects and distinctive benefits.

Gantenerumab specifically attaches to aggregated Aβ plaques, aiding in their removal of Aβ from the brain. This action has the potential to decrease the amount of plaque and enhance cognitive function. One of its benefits is its high effectiveness in lowering amyloid plaques, which are a significant characteristic of Alzheimer's disease. Nevertheless, the potential adverse consequences of this treatment could include ARIA, characterized by cerebral edema and microhemorrhages in the brain [153].

Donanemab targets the pyroglutamate-modified type of Aβ, which is known for being very toxic, to make it easier for the body to get rid of it and maybe slow the disease's progression. The main benefit of this approach is its ability to specifically target a highly toxic type of Aβ, perhaps leading to more efficient elimination of plaques and protection of neurons. Like other antibodies that target Aβ, it can also induce ARIA, resulting in adverse effects such as cerebral edema and microhemorrhages [154].

Solanezumab is a humanized monoclonal antibody that targets the mid-domain of the Aβ peptide. It makes it easier for the brain to get rid of soluble Aβ and slows down neurodegeneration. Preclinical studies have shown that it creates strong connections with Aβ, facilitating the transfer of Aβ from the brain to the plasma. This has resulted in enhanced cognitive performance in transgenic mouse models of Alzheimer's disease [155]. It attempts to inhibit the aggregation of soluble Aβ monomers into plaques. Also, it offers the benefit of a more advantageous safety profile, which typically leads to a lower incidence of serious adverse effects in comparison to other antibodies. Common side effects of this treatment may include moderate infusion-related symptoms such as chills, fever, and rash. However, the effectiveness of this treatment has shown inconsistent outcomes in clinical studies [156].

Crenezumab targets different forms of Aβ, including monomers, oligomers, and fibrils, to get rid of amyloid aggregates and lower neurotoxicity in a lot of different brain diseases. Crenezumab has a benefit due to its comprehensive targeting approach, which can address all phases of amyloid disease. The adverse effects of this medication are generally moderate; however, they may include ARIA, headaches, and infusion-related symptoms such as nausea and exhaustion [157].

In Alzheimer's disease, tilavonemab specifically targets the tau protein, which is responsible for the formation of neurofibrillary tangles. It aims to decrease tau pathology and the resulting neurodegeneration. Tilavonemab has a distinct advantage in its specific targeting of tau protein, which offers a complementary strategy to medicines that target Aβ. The typical adverse effects of this medication may include responses connected to the infusion process and headaches. However, since it is still being studied, its overall safety profile has not been fully determined [158]. Tilavonemab has shown satisfactory tolerability but did not exhibit efficacy in the treatment of early-stage Alzheimer's disease. Consequently, it is not advisable to conduct additional studies on tilavonemab for this particular disease [159, 160].

These monoclonal antibodies exemplify the diverse strategies being explored to tackle the multifaceted nature of Alzheimer's disease, each with its own mechanism of action, associated side effects, and specific advantages.

Monoclonal antibodies targeting α-syn in Parkinson’s disease

PD, DLP, MSA, and a percentage of AD are neurological diseases characterized by synucleinopathies which is an accumulation of α-syn in cortical and subcortical areas of neuronal and non-neural cells [51, 161–163]. The unique strategy for getting rid of the buildup senile particles from the brain using antibodies was logical, given that Aβ aggregates are located in the extracellular matrix (ECM) [35]. How this strategy could be applied to DLB, PD, and other synucleinopathies was unclear, as a substantial amount of Since a significant amount of proteinaceous aggregates were believed to deposit intracellularly within the neural cells of the striatonigral system, limbic areas, and deep layers of the neocortex which reflects an imbalanced proteostasis network (PN) causing neurological inflammation and failure of the synapses caused by neurodegenerative oligomer production and cell-to-cell transmission of oligomers, protofibrils, and fibrils [161, 164–166]. Nonetheless, immunizing that recently developed α-syn transgenic mice conjugated with human alpha-synuclein and Freund adjuvant resulted in the formation of elevated titer antibodies against C-terminal α-syn which were able to eliminate αlpha-syn accumulation in neural cells and alleviating functional deficits and neurodegeneration [167] via additional immunization experiments both active and passive in transgenic, viral, and injection of preformed fibrils (PFFs) [168, 169]. These antibodies act in a variety of ways, including detecting α-syn clumps in the membrane and inducing endocytosis and clearance through autophagy, lysosomal activity, or proteasomal destruction [170, 171]. Additionally, it is possible for antibodies to move within cells. With single-chain antibody fragments (scFvs) or intrabodies particularly designed to pass through the plasma membrane via apolipoprotein B (ApoB), trans-acting activator of transcription (TAT) fusion proteins, or by utilization of endogenous agonist [172, 173]. A substantial body of evidence indicates that α-Syn is not just a marker for Parkinson's disease (PD) but actively contributes to its progression [161]. Potential treatments for synucleinopathies involve reducing the accumulation of α-Syn both intracellularly and extracellularly or enhancing its clearance, which may serve as effective therapeutic approaches for Parkinson's disease (PD) and related disorders [174, 175]. The discovery of disease-causing α-Syn species and their ability to spread between cells has created new avenues for developing therapies intended to delay or stop disease progression [174]. These strategies typically involve: (1) immunization; (2) reducing the production of α-Syn protein; (3) inhibiting α-Syn oligomerization; (4) decreasing intracellular or extracellular α-Syn aggregation; (5) enhancing α-Syn clearance; (6) targeting genes/proteins that influence α-Syn aggregation or processing (e.g., silencing SNCA); (7) increasing the breakdown of α-Syn by proteolytic enzymes; (8) minimizing posttranslational changes as oxidation, nitration, phosphorylation, and C-terminal cleavage [73, 174, 176]. While these treatments show promise, many of these therapies are still in early research phases and need more clinical studies to confirm their safety and effectiveness in treating α-Syn-related disorders. Immunotherapy that targets extracellular α-Syn transmission remains crucial from a clinical standpoint [177]. In theory, antibody-based therapies are the most effective treatments for targeting pathogenic proteins, especially those located in the extracellular environment [178, 179]. On the other hand, various preclinical and clinical studies have developed alternative targeting methods to indirectly slow the spread of α-Syn (Tables 3 and 4) [138]. These approaches have long-term therapeutic promise since they restrict the extracellular release of aggregated α-Syn and prevent the propagation of pathogenic proteins, resulting in neuroprotection in PD patients. Table 3 Active and passive immunization in Parkinson's disease (PD) animal models

Name	Antibody	Model	Route of administration	Target site	Time and dose	Effect of α-Syn	Effect on behavior	References	
PDO1A AFFiRiS	AFF	PDGF, mThy1, MBP α-Syn mice	s.c	C-terminus	8 months; 80 μg/mL, 100 μL	Decreased α-Syn accumulation prevented α-Syn propagation	Motor improvements: decreased errors on round beam test	[180, 181]	
UB-312 Vaxxinity	UB-312	Thy1SNCA/15 mice (line 61)	i.m	C-terminus	15 months; 40 µg per injection	Decreased levels of α-Syn oligomer	Enhancements in motor skills, learning, and memory: decreased errors on the round beam test	[170, 182–185]	
Prasinezumab (PRX002)	9E4	PDGF, Thy1 (line D, 61)-α-Syn mice	i.p./i.v	C-terminus	6 months; 10 mg/kg	Decreased DA cell loss

Decreased Calpain-cleaved α-Syn oligomer

Decreased α-Syn accumulation

	Motor performance: increased Cylinder, Pole, and Rotarod test	[170, 171, 181]	
TAK-341	MEDI1341	Rat and cynomolgus monkey	i.v	C-terminus	13 weeks; from 3 mg/kg to 100 mg/kg; 25, 75, and 150 mg/kg	Decreased contralateral and ipsilateral α-Syn

Decreased Interstitial and CSF fluid α-Syn levels

Decreased α-Syn spread along axons

	–	[186]	
Cinpanemab	BIIB054 (NI-202)	Rat and cynomolgus monkey. A53T (M83), BAC A53T α-Syn PFF	i.p./i.v	N-terminus	2–4 months; 10 mg/kg and 30 mg/kg	Decreased α-Syn pathology maintained and improved DAT levels	Motor improvements: increased latency in time to fall in wire hang test	[187, 188]	
Syn303	–	wt mice PFF	i.p	N-terminus	180 days; 30 mg/kg	Blocked α-Syn spreading

Decreased DA cells loss

Decreased insoluble α-Syn aggregation and pS129-α-Syn

	Increased latency to hang (wire-hang time)	[169]	
Lu AF82422	–	Rat and cynomolgus monkey	i.v	C-terminus	4 weeks, 1 dose; 0–600, 0–300, and 1–30 mg/kg	Decreased α-Syn aggregation	–	[189]	
1H7, 5C1	α-Syn antibodies 1H7

5C1

5D12

	Thy1 α-Syn (line 61) mice	i.p	C-terminus	6 months; 10 mg/kg	Decreased TH loss in striatum (35%)

Decreased α-Syn accumulation

Decreased synaptophysin + MAP2

decreased astro and microgliosis

	Decreased memory and learning deficits

Decreased Error on transversal beam

Decreased Memory and learning deficits

	[181]	
AB1	Syn303	Nigral AAV-CBA α-Syn in wt rats	i.p	N-terminus	3 months; 1 mg/rat (2 × first), 0.5 mg/mL	Decreased α-Syn in SN

Decreased α-Syn brain homogenate

Decreased DA and NeuN cells loss

	Motor improvement: increased on cylinder test	[190]	

Table 4 Immunotherapeutic agents undergoing clinical trials for Parkinson's disease

Drug	Target	Mechanism of action	Phase	Clinical Trials.gov	Status	Results	References	
Prasinezumab (PRX002)	C-terminus	Aggregation α-Syn at AA 118–126	Phase II	NCT03100149	In progress, not recruiting	Safe and easily tolerated

Decreased free serum α-Syn

	[191, 192]	
Cinpanemab (BIIB054)	N-terminus	Aggregation, fibrillar α-Syn	Phase I	NCT02459886	Completed	Safe and tolerable with no TEAEs	[193]	
Cinpanemab (BIIB054)	N-terminus	Aggregation, fibrillar α-Syn	Phase II	NCT03318523	Terminated	The study failed to fulfill its intended outcome	[194]	
MEDI1341/TAK-341	C-terminus	Monomeric and Aggregation α-Syn at the AA 103–129 region	Phase I

Phase III

	NCT04449484

NCT05526391

	Completed

Recruiting

	Result pending	[186]	
UCB7853	C-terminus	Aggregation α-Syn	Phase I	NCT04651153	In progress, not recruiting	In progress	–	
PD01A AFF	C-terminus	Peptide-based vaccine	Phase I	NCT01568099	Completed	Good tolerability and safety of s.c. administration	[195]	
PD03A AFF	C-terminus	Mimics α-Syn peptide vaccination acts as B cell epitope	Phase IB

Phase I

	NCT02618941

NCT02267434

	Completed, result pending

Completed

	Safe and well tolerated	[196]	
UB-312	C-terminus	Targets oligomeric and fibrillary α-Syn	Phase IA and B	NCT04075318	Completed	Safe, easily tolerated, and induced anti-α-Syn antibodies in serum and CSF	[197]	

Limitations of immune checkpoint blockade in age-related neurodegenerative disorders

Because the brain is an immune-privileged organ, it contains defenses against the immune system’s attacks on healthy cells, immune checkpoint inhibitors find it challenging to enter the brain and find the appropriate cells [198]. Immune checkpoint inhibitors might not be able to identify and target the correct cells, even if they do enter the brain [199, 200]. This is due to the possibility that the immunological checkpoint molecules expressed by cells engaged in neurodegenerative diseases differ from those expressed by cancer cells [201, 202]. The goal of targeting immune checkpoints in cancer is to inhibit checkpoints that avoid the immune system from attacking tumor cells, whereas the goal of targeting immune checkpoints in neurodegenerative diseases is to reduce the inflammatory aspects of some neurodegenerative conditions [203]. Immune checkpoint inhibitors may potentially harm healthy cells unintentionally [204]. This is because they have the ability to interfere with ‘immunological checkpoint molecules’ interactions with the ligands on healthy cells [205]. ICIs are drugs that allow the body’s defenses to recognize and eliminate cells that are cancerous [206]. ICIs, which have been created for dealing with late-stage cancer, have lately grown in significance in oncology [206, 207]. Furthermore, several research found that these therapies are successful in easing and even correcting cognitive deficits as well as lowering disease pathology [208]. On the other hand, this can lead to a wide range of immune-related adverse events [209].

The neurological immune-related adverse effects

Encephalitis is one of the many immunological-related side effects that ICIs can trigger. The patient first had quickly been developing disorientation, a decreased state of awareness, headache, seizures, and localized neurological abnormalities. So, in patients receiving ICIs who report quickly developing confusion, encephalitis should be suspected [209]. Guillain–Barré syndrome, leukoencephalopathy, polyneuropathy, myelopathy, myasthenia gravis (MG), demyelination, facial nerve palsy, enteric neuropathy, enteric neuropathy, aseptic meningitis, transverse myelitis, and myositis are among the neurological problems caused by ICIs as shown in Fig. 4 [210, 211]. Symptoms of MG which occurred after ICI therapy had not been as “benign” as typical MG and, without a doubt, need recognition and concern with a greater degree of severity. Immune-related MG (irMG) is an uncommon but potentially lethal consequence. Anaerobic pneumonia and hypercapnic respiratory failure, which causes paralysis of the bulbar, were among the irMG-related fatalities. Diaphragmatic paralysis is the primary reason for mortality with irMG. Although irMG is uncommon, with the increased usage of ICIs, the number of people with irMG is expected to skyrocket [211].Fig. 4 Adverse effects of immune checkpoint inhibitors in age-related neurodegenerative disorders

The cardiovascular immune-related adverse effects

Immune-related myocarditis is a potentially lethal non-neurological immune-related adverse event. A recent study indicated that diplopia and/or ptosis were symptoms of irMG and/or irMyopathy impacting ocular muscles, as well as asymptomatic myocarditis. Elevated levels of desmin and troponin (muscle-specific antigens) were found in both patients tumors, indicating the notion that targeting of skeletal and cardiac muscle stems from specific antigens found in the skeletal muscle, myocardium, and tumors that identical T-cell clones recognize them. As a result, ICIs patients with myositis of the ocular muscles should trigger further investigation of other muscles, especially the heart muscle [212]. The effects of ICIs on cardiovascular are more than just myocarditis. It is probably the most devastating immune-related cardiovascular complication, although there have also been reports of conduction problems, vasculitis, non-inflammatory heart failure, and pericardial disease. Freshly, data suggest that ICIs play a role in speeding atherosclerosis and boosting plaque inflammation, ultimately resulting in myocardial infarction as shown in Fig. 4 [213].

Pre-existing autoimmune disease as a risk factor on cardiovascular safety

Myocarditis, arrhythmias, coronary syndromes, vasculitis, pericarditis, acute cardiomyopathy, and conduction abnormalities have all been documented as cardiovascular events (CVEs) [214–216]. With the rising use of ICIs, there has been significant concern about the health effects of ICI therapy in patients who have pre-existing autoimmune diseases, because these individuals are prone to aberrant anti-self-immune reactions [217, 218]. As a result, safety is restricted. Before beginning ICI therapy, patients should have an inclusive cardiovascular history taken, as well as a history of autoimmune illness [219].

Potential strategies to overcome the limitations of immune checkpoint blockade

Although immunotherapy using ICIs is definitely one of the most promising techniques for the treatment of cancer and neurological illnesses, significant hurdles remain (e.g., low response rate, acquired resistance, and adverse events). A minority of individuals develop primary resistance to early immunotherapy, but the vast majority develop acquired resistance to ICIs [220]. Combination therapy, targeting alternative immune checkpoints, translational research, and biomarker identification are some of the potential options being investigated to overcome these constraints [220–222]. Combination therapy with different medications can help overcome immune checkpoint inhibitor resistance. Combining immune checkpoint inhibitors with other immunotherapies or chemotherapy, can increase response rates and overall survival [221]. Even so, the mechanisms underlying the development of ICB drug resistance are unclear [222]. Recently, several studies suggested that combining ICIs with anti-angiogenic drugs might be a potential treatment approach for overcoming the low efficacy of ICIs [220]. Targeting alternative immune checkpoints is a promising strategy that many studies supports. Alternative immune checkpoints such as T cell immunoglobulin and mucin-domain containing-3 (TIM-3), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), and ligand lymphocyte activation gene-3 (LAG-3) can assist in overcoming PD-1 resistance [223]. In addition, there are many other immune checkpoints that could be targeted by ICB therapy. For example, targeting the PD-L2 checkpoint has shown promise in clinical trials [224]. Furthermore, translational studies and biomarker identification can help in decreasing the immune-related adverse events (irAEs) rate. Identifying biomarkers which predict response to ICIs can help select patients who will benefit the most from therapy. This can assist in eliminating wasteful therapy in patients who are unlikely to react, allowing for more personalized treatment [220, 225].

Neurological immune-related AEs to manage

Because of the specific method of action of ICIs, they exhibit their own set of irAEs, as mentioned previously. Although neurologic immune-related AEs are infrequent, they are an arising area of concern due to the intricacies of the nervous system and the likelihood of long-term morbidity [214, 226]. Polyneuropathy, demyelination, 7th nerve palsy, MG, postinfectious polyneuritis, posterior reversible leukoencephalopathy, enteric neuropathy, transverse myelitis, encephalitis, and viral meningitis are among the neurologic occurrences recorded. It is crucial to exclude underlying malignant tumor progression, activity related to seizures, metabolic imbalance, and infection as potential reasons for neurological dysfunction [210]. There is a low threshold for withholding ICI medication in situations where symptoms are indicative of probable neurological damage, even if symptoms are of 'Grade 1' (mild) intensity. Corticosteroid medication should be started right away in patients with overt, progressing symptoms that have a functional impact (whether moderate or severe), and inpatient hospitalization should be considered. If there is any involvement of the respiratory muscles, patients should be admitted to centers where ventilation may be easily supported. An approach to investigation and management is summarized in Table 5 [227]. Table 5 An approach to the investigation and management of neurologic immune-related adverse events

Symptom grade	Diagnostic investigations	Management	
Grade 1 (mild): no interference with function	History and neurological examination

U&E, FBC, HbA1c, LFTs, TFTs, MMA, B12/Folate, HIV, homocysteine, and Autoimmune screen

	Low threshold to hold ICPi and monitoring symptoms for progression	
Grade 2 (moderate): some interference with ADLs

NB: any cranial nerve involvement

	Suspected Central disorder

- MRI Head ± spine (T1, T2, STIR ± GAD)

- Lumber Puncture- CSF + OCB and Viral PCR

- Antibodies (NMDAR, LGi1, CASPR2, MOG, AQP4 and paraneoplastic)

	- Withhold ICPi

- Initial observation OR 0.5-1 mg/kg Prednisolone

- Specialist neurology input

- Empiric antibacterial and antivirals (encephalitis/meningitis)

	
Suspected peripheral disorder

- CK, ganglioside ab, AChR/MuSK ab, myositis ab panel, ± vasculitis screen

- NCS, EMG (± SFEMG, RNS)

	- Withhold ICPi

- Initial observation OR 0.5-1 mg/kg Prednisolone

- Specialist neurology input

	
Grade 3/4 (severe): limits self-care and aids warranted

Respiratory symptomatology, e.g., dyspnea

	Suspected central disorder

- MRI head

- Lumbar puncture- CSF + OCB and Viral PCR (suspicion of meningitis/ encephalitis)

- Antibodies as above

	- Admit patient

- Permanently discontinue ICPi

- IV methylprednisolone 2 mg/kg

- Specialist neurology input

- Empiric antibacterial and antivirals (CSF lymphocytosis or pyrexia

	
Suspected peripheral disorder

- Neurophysiology (RNS, SFEMG, EMG, NCS)

- CK, ganglioside ab, AChR/MuSKab, myositis ab panel, ± vasculitis screen

- Spirometry: FVC, FEV1 lying and standing (if neuromuscular respiratory involvement)

- ECG/ cardiac monitoring if myositis or GBS presentation

- Consider nerve/ muscle biopsy

	- Admit patient and consider need for ICU admission

- Permanently discontinue ICPi

- IV methylprednisolone 2 mg/kg

- Specialist neurology input

- IVIG/ plasmapheresis

	

Discussion

Neurodegenerative disorders encompass a variety of progressive diseases marked by the slow degeneration of nerve cells in either the brain or the peripheral nervous system. These illnesses, such as Alzheimer's disease and Parkinson's disease, cause a range of cognitive and motor deficits that worsen over time [228]. Alzheimer's disease is the predominant kind, characterized by memory loss, cognitive decline, and changes in behavior. Millions of individuals worldwide are affected by it, and it frequently results in death [229]. Meanwhile, Parkinson's disease primarily impacts motor function, leading to tremors, stiffness, and impaired balance. While not as common as Alzheimer's, Parkinson's disease also has a substantial impact on life expectancy. Both diseases pose difficulties for the healthcare sector due to their chronic nature and significant impact on patients quality of life [230].

Stem cell therapy, gene therapy, and the administration of medicines like metformin and rapamycin showed promise in treating neurodegenerative diseases. For example, stem cell therapy can decrease the accumulation of amyloid-beta, enhance cognitive function, and control motor symptoms in Alzheimer's disease by the transplantation of dopaminergic precursors [231]. However, the area faces challenges including the need for neurosurgical treatments, potential dangers associated with immunosuppression, and reported cases of tumor growth in both human and rodent studies [232–234]. In order to address these problems, further investigation is required to control the proliferation and specialization of stem cells, improve precision in targeting by utilizing molecular markers, develop effective delivery techniques, and allow the genetic and clinical diversities observed in individuals with Alzheimer's disease. While preclinical findings are encouraging, clinical trials are currently in their initial stages. Therefore, it is imperative to establish standard protocols and carry out a thorough examination to determine the safety, effectiveness, and enduring impacts of these treatments for neurodegenerative diseases.

Furthermore, notable advancements have been achieved in the management of neurodegenerative disorders, such as Alzheimer's disease, with the creation of specific treatments like aducanumab and lecanemab. Each target specifically targets the fundamental disease pathways that have the potential to produce significant clinical outcomes but may also result in distinct side effects identified during studies.

Aducanumab, approved by the FDA in 2021, targets amyloid-beta plaques, a pivotal factor in Alzheimer's disease progression. According to preclinical research and clinical trials, aducanumab may improve neurological function by lowering Aß plaques and increasing neuronal calcium permeability [235]. The ENGAGE and EMERGE trials demonstrated significant reductions in amyloid plaques, underscoring aducanumab's therapeutic potential. Aducanumab has also been linked to several adverse effects. Headache, diarrhea, and other constitutional symptoms are the most often reported. ARIA-E is among the most severe adverse effects seen in anti-Aβ monoclonal antibody therapy, including aducanumab [236]. Avgerinos et al. conducted a meta-analysis which revealed that aducanumab had the highest chance of developing ARIA-E when compared to other anti-Aβ antibody immunotherapies [237]. While deaths have been reported with other anti-Aβ immunotherapy treatments like bapineuzumab and solanezumab, no deaths have been associated with aducanumab in Alzheimer's disease treatment [238–240].

On the other hand, disparities in post hoc analysis have sparked doubt in the scientific and medical communities. Some studies indicate that while aducanumab's effects show statistical significance, their clinical relevance remains uncertain [241–243]. Critics argue that the FDA's initial denial of aducanumab approval may have been overly cautious and not fully considered other relevant aspects [244]. Confounding variables may have contributed to differences observed between the EMERGE and ENGAGE trials, emphasizing the need for additional studies to bolster confidence in aducanumab's efficacy [241]. Despite these concerns, aducanumab consistently demonstrated significant reductions in amyloid across all examined cortical brain regions [236, 245].

On the other hand, lecanemab specifically targets tau protein aggregates, which are also a characteristic feature of Alzheimer's disease. Further trials are presently assessing its efficacy and safety. The primary adverse effects are infusion-related reactions, which are typical with monoclonal antibody therapies [246]. These medications show targeted approaches to treating AD, emphasizing the importance of precisely balancing therapeutic efficacy with safety considerations during the development of treatment options for Alzheimer's disease.

Developing immunotherapy to target α-Syn aggregates in synucleinopathies like Parkinson's disease is a multifaceted challenge that demands a comprehensive strategy rooted in the latest scientific insights. Preclinical trials investigating treatments aimed at reducing α-Syn aggregates and improving motor and cognitive abilities in experimental animals have shown promising results [171, 180–182]. These findings suggest potential therapeutic benefits for α-Syn targeting in neurodegenerative diseases.

However, the translation of these promising preclinical outcomes to clinical trials has proven complex and variable. Clinical studies evaluating immunotherapeutic drugs directed at α-Syn have produced mixed results. For instance, BIIB054/cinpanemab, which targets the N-terminus of α-Syn, did not meet expectations in a pivotal phase II trial [188]. On the other hand, PRX002/prasinezumab, which targets the C-terminus of α-Syn, showed favorable results in secondary endpoints, prompting the commencement of a phase IIB trial [193, 247].

These discrepancies highlight the challenges and uncertainties in moving from preclinical success to clinical efficacy in treating neurodegenerative diseases. Issues such as target specificity, dosing protocols, and patient heterogeneity can significantly influence trial outcomes. Therefore, further research and larger-scale studies are essential to elucidate the potential of α-Syn-targeting immunotherapies in clinical practice.

Moreover, recent findings from clinical trials, such as NCT03318523 (clinicaltrials.gov/ct2/show/NCT03318523), underscore the difficulty in translating biomarker discoveries into meaningful clinical impacts. While these trials enrolled early Parkinson's disease patients meeting biomarker criteria, they did not establish clear links between disease progression and treatment effects on biomarker measurements like those of cinpanemab. This underscores the ongoing need for reliable biomarkers that accurately gauge early PD progression. Such biomarkers could not only accelerate the development of tailored therapies, but also enhance the efficacy of immunotherapy strategies for managing synucleinopathies.

Both aducanumab and α-Syn-targeting immunotherapy are advanced approaches in the treatment of neurodegenerative diseases. Continued research endeavors are essential to gain a deeper understanding of their mechanisms, refine therapeutic treatments, and validate their clinical advantages. Realizing the full therapeutic promise of these novel techniques in treating Alzheimer's disease and synucleinopathies such as Parkinson's disease will require advancing our understanding of disease biology, enhancing treatment specificity, and discovering potent biomarkers.

Conclusions

Recent studies show that various immunotherapies, both active and passive, can significantly improve outcomes in AD and PD. Aducanumab and lecanemab, targeting Aβ and tau aggregates in AD, respectively, are notable advancements. Aducanumab, FDA-approved in 2021, reduces Aβ plaques but has side effects like ARIA-E. Research is ongoing to validate its clinical relevance despite mixed trial results.

Immunotherapy for PD targeting α-syn shows promise but faces challenges such as crossing the BBB and achieving clinical efficacy. Biomarkers are key for tracking disease and treatment progress, though most research is in animal models. The human applicability of α-syn processes remains unclear. Some reviewed studies did not demonstrate the efficacy of α-syn antibodies in PD, but future technological advancements may address these issues.

Abbreviations

AD Alzheimer's disease

PD Parkinson's disease

MSCs Mesenchymal stem cells

Aβ Amyloid-beta-peptide

AD-MSCs Adipose tissue-derived mesenchymal stem cells

PDD Parkinson's disease dementia

NMDA N-Methyl-d-aspartate

AAV Adeno-associated virus

PD-1 Programmed cell death protein 1

APCs Antigen-presenting cells

ICIs Immune checkpoint inhibitors

TCR T cell receptor

EAE Experimental autoimmune encephalomyelitis

MHC Major histocompatibility complex

Th1 T helper cell 1

SCI Spinal cord injury

FDA Food and Drug Administration

ARIA-E Amyloid-related imaging abnormalities-edema

ARIA-H Amyloid-related imaging abnormalities-cerebral microhemorrhage

IgG1 Immunoglobulin 1

MCI Mild cognitive impairment

ICB Immune checkpoint blockade

MG Myasthenia gravis

IrMG Immune-related MG

IrMyopathy Immune-related myopathy

CVEs Cardiovascular events

CTLA-4 Cytotoxic T lymphocyte-associated protein 4

TIM-2 T cell immunoglobulin and mucin-domain containing-3

LAG-3 Ligand lymphocyte activation gene-3

PD-L2 Programmed cell death-ligand 2

IrAEs Immune-related adverse events

AChR Acetylcholine receptor

HbA1c Glycated hemoglobin

ICI Immune checkpoint inhibitor

Author contributions

Noha N Lasheen, Salma Allam, Abdullrahman Elgarawany, Darin.W.Aswa, Rana Mansour and Ziad Farouk participated in writing the review article. Noha N Lasheen Edited and reviewed the final revision of the review. Noha N Lasheen supervised the research point. All authors approved the final revision of the review article.

Funding

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Availability of data and materials

No data associated in the manuscript.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors have no relevant financial or non-financial interests to disclose.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Aguilar-Hernández L Alejandre R César Morales-Medina J Cellular mechanisms in brain aging: focus on physiological and pathological aging J Chem Neuroanat 2023 128 102210 10.1016/j.jchemneu.2022.102210 36496000
Aguilar-Hernández L, Alejandre R, César Morales-Medina J et al (2023) Cellular mechanisms in brain aging: focus on physiological and pathological aging. J Chem Neuroanat 128:102210. 10.1016/j.jchemneu.2022.10221036496000
2. Sacco A Belloni L Latella L From development to aging: the path to cellular senescence Antioxid Redox Signal 2021 34 294 307 10.1089/ars.2020.8071 32228062
Sacco A, Belloni L, Latella L (2021) From development to aging: the path to cellular senescence. Antioxid Redox Signal 34:294–307. 10.1089/ars.2020.807132228062
3. Aunan JR Watson MM Hagland HR Søreide K Molecular and biological hallmarks of ageing Br J Surg 2016 103 e29 e46 10.1002/bjs.10053 26771470
Aunan JR, Watson MM, Hagland HR, Søreide K (2016) Molecular and biological hallmarks of ageing. Br J Surg 103:e29–e46. 10.1002/bjs.1005326771470
4. Hao L-Y Armanios M Strong MA Short telomeres, even in the presence of telomerase, limit tissue renewal capacity Cell 2005 123 1121 1131 10.1016/j.cell.2005.11.020 16360040
Hao L-Y, Armanios M, Strong MA et al (2005) Short telomeres, even in the presence of telomerase, limit tissue renewal capacity. Cell 123:1121–1131. 10.1016/j.cell.2005.11.02016360040
5. Ding Z Wu C-J Jaskelioff M Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases Cell 2012 148 896 907 10.1016/j.cell.2012.01.039 22341455
Ding Z, Wu C-J, Jaskelioff M et al (2012) Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 148:896–907. 10.1016/j.cell.2012.01.03922341455
6. Zhao Y Simon M Seluanov A Gorbunova V DNA damage and repair in age-related inflammation Nat Rev Immunol 2023 23 75 89 10.1038/s41577-022-00751-y 35831609
Zhao Y, Simon M, Seluanov A, Gorbunova V (2023) DNA damage and repair in age-related inflammation. Nat Rev Immunol 23:75–89. 10.1038/s41577-022-00751-y35831609
7. Stead ER Bjedov I Balancing DNA repair to prevent ageing and cancer Exp Cell Res 2021 405 112679 10.1016/j.yexcr.2021.112679 34102225
Stead ER, Bjedov I (2021) Balancing DNA repair to prevent ageing and cancer. Exp Cell Res 405:112679. 10.1016/j.yexcr.2021.11267934102225
8. Zhu D Li X Tian Y Mitochondrial-to-nuclear communication in aging: an epigenetic perspective Trends Biochem Sci 2022 47 645 659 10.1016/j.tibs.2022.03.008 35397926
Zhu D, Li X, Tian Y (2022) Mitochondrial-to-nuclear communication in aging: an epigenetic perspective. Trends Biochem Sci 47:645–659. 10.1016/j.tibs.2022.03.00835397926
9. Zhao Q Liu J Deng H Targeting mitochondria-located circRNA SCAR alleviates NASH via reducing mROS output Cell 2020 183 76 93.e22 10.1016/j.cell.2020.08.009 32931733
Zhao Q, Liu J, Deng H et al (2020) Targeting mitochondria-located circRNA SCAR alleviates NASH via reducing mROS output. Cell 183:76-93.e22. 10.1016/j.cell.2020.08.00932931733
10. Igarashi M Miura M Williams E NAD+ supplementation rejuvenates aged gut adult stem cells Aging Cell 2019 18 e12935 10.1111/acel.12935 30917412
Igarashi M, Miura M, Williams E et al (2019) NAD+ supplementation rejuvenates aged gut adult stem cells. Aging Cell 18:e12935. 10.1111/acel.1293530917412
11. Xie N Zhang L Gao W NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential Signal Transduct Target Ther 2020 5 227 10.1038/s41392-020-00311-7 33028824
Xie N, Zhang L, Gao W et al (2020) NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct Target Ther 5:227. 10.1038/s41392-020-00311-733028824
12. Cassidy LD Narita M Autophagy at the intersection of aging, senescence, and cancer Mol Oncol 2022 16 3259 3275 10.1002/1878-0261.13269 35689420
Cassidy LD, Narita M (2022) Autophagy at the intersection of aging, senescence, and cancer. Mol Oncol 16:3259–3275. 10.1002/1878-0261.1326935689420
13. Kaushik S Tasset I Arias E Autophagy and the hallmarks of aging Ageing Res Rev 2021 72 101468 10.1016/j.arr.2021.101468 34563704
Kaushik S, Tasset I, Arias E et al (2021) Autophagy and the hallmarks of aging. Ageing Res Rev 72:101468. 10.1016/j.arr.2021.10146834563704
14. Kalamakis G Brüne D Ravichandran S Quiescence modulates stem cell maintenance and regenerative capacity in the aging brain Cell 2019 176 1407 1419.e14 10.1016/j.cell.2019.01.040 30827680
Kalamakis G, Brüne D, Ravichandran S et al (2019) Quiescence modulates stem cell maintenance and regenerative capacity in the aging brain. Cell 176:1407–1419.e14. 10.1016/j.cell.2019.01.04030827680
15. Schneider JL Rowe JH Garcia-de-Alba C The aging lung: physiology, disease, and immunity Cell 2021 184 1990 2019 10.1016/j.cell.2021.03.005 33811810
Schneider JL, Rowe JH, Garcia-de-Alba C et al (2021) The aging lung: physiology, disease, and immunity. Cell 184:1990–2019. 10.1016/j.cell.2021.03.00533811810
16. Holwerda AM Paulussen KJM Overkamp M Dose-dependent increases in whole-body net protein balance and dietary protein-derived amino acid incorporation into myofibrillar protein during recovery from resistance exercise in older men J Nutr 2019 149 221 230 10.1093/jn/nxy263 30722014
Holwerda AM, Paulussen KJM, Overkamp M et al (2019) Dose-dependent increases in whole-body net protein balance and dietary protein-derived amino acid incorporation into myofibrillar protein during recovery from resistance exercise in older men. J Nutr 149:221–230. 10.1093/jn/nxy26330722014
17. Slack C Alic N Foley A The Ras-Erk-ETS-signaling pathway is a drug target for longevity Cell 2015 162 72 83 10.1016/j.cell.2015.06.023 26119340
Slack C, Alic N, Foley A et al (2015) The Ras-Erk-ETS-signaling pathway is a drug target for longevity. Cell 162:72–83. 10.1016/j.cell.2015.06.02326119340
18. Fafián-Labora JA O’Loghlen A Classical and nonclassical intercellular communication in senescence and ageing Trends Cell Biol 2020 30 628 639 10.1016/j.tcb.2020.05.003 32505550
Fafián-Labora JA, O’Loghlen A (2020) Classical and nonclassical intercellular communication in senescence and ageing. Trends Cell Biol 30:628–639. 10.1016/j.tcb.2020.05.00332505550
19. Yang BA Westerhof TM Sabin K Engineered tools to study intercellular communication Adv Sci 2021 8 2002825 10.1002/advs.202002825
Yang BA, Westerhof TM, Sabin K et al (2021) Engineered tools to study intercellular communication. Adv Sci 8:2002825. 10.1002/advs.202002825
20. Villeda SA Luo J Mosher KI The ageing systemic milieu negatively regulates neurogenesis and cognitive function Nature 2011 477 90 94 10.1038/nature10357 21886162
Villeda SA, Luo J, Mosher KI et al (2011) The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477:90–94. 10.1038/nature1035721886162
21. DeJong EN Surette MG Bowdish DME The gut microbiota and unhealthy aging: disentangling cause from consequence Cell Host Microbe 2020 28 180 189 10.1016/j.chom.2020.07.013 32791111
DeJong EN, Surette MG, Bowdish DME (2020) The gut microbiota and unhealthy aging: disentangling cause from consequence. Cell Host Microbe 28:180–189. 10.1016/j.chom.2020.07.01332791111
22. Alsegiani AS Shah ZA The influence of gut microbiota alteration on age-related neuroinflammation and cognitive decline Neural Regen Res 2022 17 2407 2412 10.4103/1673-5374.335837 35535879
Alsegiani AS, Shah ZA (2022) The influence of gut microbiota alteration on age-related neuroinflammation and cognitive decline. Neural Regen Res 17:2407–2412. 10.4103/1673-5374.33583735535879
23. Ageing and health. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health. Accessed 16 Sep 2023
24. Dementia. https://www.who.int/news-room/fact-sheets/detail/dementia. Accessed 16 Sep 2023
25. Hurd MD, Martorell P, Langa KM (2013) Monetary costs of dementia in the United States. N Engl J Med 369:489–490. 10.1056/NEJMc1305541
26. Selkoe DJ Cell biology of protein misfolding: the examples of Alzheimer’s and Parkinson’s diseases Nat Cell Biol 2004 6 1054 1061 10.1038/ncb1104-1054 15516999
Selkoe DJ (2004) Cell biology of protein misfolding: the examples of Alzheimer’s and Parkinson’s diseases. Nat Cell Biol 6:1054–1061. 10.1038/ncb1104-105415516999
27. Taylor JP Hardy J Fischbeck KH Toxic proteins in neurodegenerative disease Science 2002 296 1991 1995 10.1126/science.1067122 12065827
Taylor JP, Hardy J, Fischbeck KH (2002) Toxic proteins in neurodegenerative disease. Science 296:1991–1995. 10.1126/science.106712212065827
28. Ballard C Gauthier S Corbett A Alzheimer’s disease Lancet Lond Engl 2011 377 1019 1031 10.1016/S0140-6736(10)61349-9
Ballard C, Gauthier S, Corbett A et al (2011) Alzheimer’s disease. Lancet Lond Engl 377:1019–1031. 10.1016/S0140-6736(10)61349-9
29. Dhana K Evans DA Rajan KB Healthy lifestyle and the risk of Alzheimer dementia: findings from 2 longitudinal studies Neurology 2020 95 e374 e383 10.1212/WNL.0000000000009816 32554763
Dhana K, Evans DA, Rajan KB et al (2020) Healthy lifestyle and the risk of Alzheimer dementia: findings from 2 longitudinal studies. Neurology 95:e374–e383. 10.1212/WNL.000000000000981632554763
30. Ferrer I Hypothesis review: Alzheimer’s overture guidelines Brain Pathol 2023 33 e13122 10.1111/bpa.13122 36223647
Ferrer I (2023) Hypothesis review: Alzheimer’s overture guidelines. Brain Pathol 33:e13122. 10.1111/bpa.1312236223647
31. Hardy J Selkoe DJ The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics Science 2002 297 353 356 10.1126/science.1072994 12130773
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356. 10.1126/science.107299412130773
32. Price DL Whitehouse PJ Struble RG Alzheimer’s disease Annu Rev Med 1985 36 349 356 10.1146/annurev.me.36.020185.002025 2859830
Price DL, Whitehouse PJ, Struble RG (1985) Alzheimer’s disease. Annu Rev Med 36:349–356. 10.1146/annurev.me.36.020185.0020252859830
33. Akiyama H Barger S Barnum S Inflammation and Alzheimer’s disease Neurobiol Aging 2000 21 383 421 10.1016/S0197-4580(00)00124-X 10858586
Akiyama H, Barger S, Barnum S et al (2000) Inflammation and Alzheimer’s disease. Neurobiol Aging 21:383–421. 10.1016/S0197-4580(00)00124-X10858586
34. Wyss-Coray T Mucke L Inflammation in neurodegenerative disease—a double-edged sword Neuron 2002 35 419 432 10.1016/s0896-6273(02)00794-8 12165466
Wyss-Coray T, Mucke L (2002) Inflammation in neurodegenerative disease—a double-edged sword. Neuron 35:419–432. 10.1016/s0896-6273(02)00794-812165466
35. Schenk D Barbour R Dunn W Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 1999 400 173 177 10.1038/22124 10408445
Schenk D, Barbour R, Dunn W et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173–177. 10.1038/2212410408445
36. Weiner HL Lemere CA Maron R Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer’s disease Ann Neurol 2000 48 567 579 10.1002/1531-8249(200010)48:4<567::AID-ANA3>3.0.CO;2-W 11026440
Weiner HL, Lemere CA, Maron R et al (2000) Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer’s disease. Ann Neurol 48:567–57911026440
37. ADAPT Research GroupMartin BK Szekely C Cognitive function over time in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib Arch Neurol 2008 65 896 905 10.1001/archneur.2008.65.7.nct70006 18474729
ADAPT Research Group, Martin BK, Szekely C et al (2008) Cognitive function over time in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65:896–905. 10.1001/archneur.2008.65.7.nct7000618474729
38. Arvanitakis Z Grodstein F Bienias JL Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology Neurology 2008 70 2219 2225 10.1212/01.wnl.0000313813.48505.86 18519870
Arvanitakis Z, Grodstein F, Bienias JL et al (2008) Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 70:2219–2225. 10.1212/01.wnl.0000313813.48505.8618519870
39. Breitner JCS Haneuse SJPA Walker R Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort Neurology 2009 72 1899 1905 10.1212/WNL.0b013e3181a18691 19386997
Breitner JCS, Haneuse SJPA, Walker R et al (2009) Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 72:1899–1905. 10.1212/WNL.0b013e3181a1869119386997
40. Orgogozo J-M Gilman S Dartigues J-F Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization Neurology 2003 61 46 54 10.1212/01.WNL.0000073623.84147.A8 12847155
Orgogozo J-M, Gilman S, Dartigues J-F et al (2003) Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61:46–54. 10.1212/01.WNL.0000073623.84147.A812847155
41. Senior K Dosing in phase II trial of Alzheimer’s vaccine suspended Lancet Neurol 2002 1 3 10.1016/s1474-4422(02)00023-6 12849527
Senior K (2002) Dosing in phase II trial of Alzheimer’s vaccine suspended. Lancet Neurol 1:3. 10.1016/s1474-4422(02)00023-612849527
42. Doody RS Raman R Farlow M A phase 3 trial of semagacestat for treatment of Alzheimer’s disease N Engl J Med 2013 369 341 350 10.1056/NEJMoa1210951 23883379
Doody RS, Raman R, Farlow M et al (2013) A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med 369:341–350. 10.1056/NEJMoa121095123883379
43. Gilman S Koller M Black RS Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial Neurology 2005 64 1553 1562 10.1212/01.WNL.0000159740.16984.3C 15883316
Gilman S, Koller M, Black RS et al (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553–1562. 10.1212/01.WNL.0000159740.16984.3C15883316
44. Dauer W Przedborski S Parkinson’s disease: mechanisms and models Neuron 2003 39 889 909 10.1016/s0896-6273(03)00568-3 12971891
Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39:889–909. 10.1016/s0896-6273(03)00568-312971891
45. Dexter DT Jenner P Parkinson disease: from pathology to molecular disease mechanisms Free Radic Biol Med 2013 62 132 144 10.1016/j.freeradbiomed.2013.01.018 23380027
Dexter DT, Jenner P (2013) Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 62:132–144. 10.1016/j.freeradbiomed.2013.01.01823380027
46. Bennett DA Beckett LA Murray AM Prevalence of parkinsonian signs and associated mortality in a community population of older people N Engl J Med 1996 334 71 76 10.1056/NEJM199601113340202 8531961
Bennett DA, Beckett LA, Murray AM et al (1996) Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 334:71–76. 10.1056/NEJM1996011133402028531961
47. Hawkes CH Parkinson’s disease and aging: same or different process? Mov Disord Off J Mov Disord Soc 2008 23 47 53 10.1002/mds.21766
Hawkes CH (2008) Parkinson’s disease and aging: same or different process? Mov Disord Off J Mov Disord Soc 23:47–53. 10.1002/mds.21766
48. Olanow CW Tatton WG Etiology and pathogenesis of Parkinson’s disease Annu Rev Neurosci 1999 22 123 144 10.1146/annurev.neuro.22.1.123 10202534
Olanow CW, Tatton WG (1999) Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci 22:123–144. 10.1146/annurev.neuro.22.1.12310202534
49. Polymeropoulos MH Lavedan C Leroy E Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease Science 1997 276 2045 2047 10.1126/science.276.5321.2045 9197268
Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047. 10.1126/science.276.5321.20459197268
50. Singleton AB Farrer M Johnson J Alpha-Synuclein locus triplication causes Parkinson’s disease Science 2003 302 841 10.1126/science.1090278 14593171
Singleton AB, Farrer M, Johnson J et al (2003) Alpha-Synuclein locus triplication causes Parkinson’s disease. Science 302:841. 10.1126/science.109027814593171
51. Spillantini MG Schmidt ML Lee VM Alpha-synuclein in Lewy bodies Nature 1997 388 839 840 10.1038/42166 9278044
Spillantini MG, Schmidt ML, Lee VM et al (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840. 10.1038/421669278044
52. Gibb WR Lees AJ The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease J Neurol Neurosurg Psychiatry 1988 51 745 752 10.1136/jnnp.51.6.745 2841426
Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51:745–752. 10.1136/jnnp.51.6.7452841426
53. Cookson MR Alpha-Synuclein and neuronal cell death Mol Neurodegen 2009 4 9 10.1186/1750-1326-4-9
Cookson MR (2009) Alpha-Synuclein and neuronal cell death. Mol Neurodegen 4:9. 10.1186/1750-1326-4-9
54. Jellinger KA More frequent Lewy bodies but less frequent Alzheimer-type lesions in multiple system atrophy as compared to age-matched control brains Acta Neuropathol (Berl) 2007 114 299 303 10.1007/s00401-007-0227-4 17476513
Jellinger KA (2007) More frequent Lewy bodies but less frequent Alzheimer-type lesions in multiple system atrophy as compared to age-matched control brains. Acta Neuropathol (Berl) 114:299–303. 10.1007/s00401-007-0227-417476513
55. Sanchez-Guajardo V Febbraro F Kirik D Romero-Ramos M Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson’s disease PLoS ONE 2010 5 e8784 10.1371/journal.pone.0008784 20098715
Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M (2010) Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson’s disease. PLoS ONE 5:e8784. 10.1371/journal.pone.000878420098715
56. Epelman S Lavine KJ Randolph GJ Origin and functions of tissue macrophages Immunity 2014 41 21 35 10.1016/j.immuni.2014.06.013 25035951
Epelman S, Lavine KJ, Randolph GJ (2014) Origin and functions of tissue macrophages. Immunity 41:21–35. 10.1016/j.immuni.2014.06.01325035951
57. Hammond TR Robinton D Stevens B Microglia and the brain: complementary partners in development and disease Annu Rev Cell Dev Biol 2018 34 523 544 10.1146/annurev-cellbio-100616-060509 30089221
Hammond TR, Robinton D, Stevens B (2018) Microglia and the brain: complementary partners in development and disease. Annu Rev Cell Dev Biol 34:523–544. 10.1146/annurev-cellbio-100616-06050930089221
58. Hanisch U-K Kettenmann H Microglia: active sensor and versatile effector cells in the normal and pathologic brain Nat Neurosci 2007 10 1387 1394 10.1038/nn1997 17965659
Hanisch U-K, Kettenmann H (2007) Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10:1387–1394. 10.1038/nn199717965659
59. Nimmerjahn A Kirchhoff F Helmchen F Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo Science 2005 308 1314 1318 10.1126/science.1110647 15831717
Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308:1314–1318. 10.1126/science.111064715831717
60. Schafer DP Lehrman EK Kautzman AG Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner Neuron 2012 74 691 705 10.1016/j.neuron.2012.03.026 22632727
Schafer DP, Lehrman EK, Kautzman AG et al (2012) Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74:691–705. 10.1016/j.neuron.2012.03.02622632727
61. Streit WJ Sammons NW Kuhns AJ Sparks DL Dystrophic microglia in the aging human brain Glia 2004 45 208 212 10.1002/glia.10319 14730714
Streit WJ, Sammons NW, Kuhns AJ, Sparks DL (2004) Dystrophic microglia in the aging human brain. Glia 45:208–212. 10.1002/glia.1031914730714
62. Streit WJ Braak H Xue Q-S Bechmann I Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer’s disease Acta Neuropathol (Berl) 2009 118 475 485 10.1007/s00401-009-0556-6 19513731
Streit WJ, Braak H, Xue Q-S, Bechmann I (2009) Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer’s disease. Acta Neuropathol (Berl) 118:475–485. 10.1007/s00401-009-0556-619513731
63. Shahidehpour RK Higdon RE Crawford NG Dystrophic microglia are associated with neurodegenerative disease and not healthy aging in the human brain Neurobiol Aging 2021 99 19 27 10.1016/j.neurobiolaging.2020.12.003 33422891
Shahidehpour RK, Higdon RE, Crawford NG et al (2021) Dystrophic microglia are associated with neurodegenerative disease and not healthy aging in the human brain. Neurobiol Aging 99:19–27. 10.1016/j.neurobiolaging.2020.12.00333422891
64. Caldeira C Cunha C Vaz AR Key aging-associated alterations in primary microglia response to beta-amyloid stimulation Front Aging Neurosci 2017 9 277 10.3389/fnagi.2017.00277 28912710
Caldeira C, Cunha C, Vaz AR et al (2017) Key aging-associated alterations in primary microglia response to beta-amyloid stimulation. Front Aging Neurosci 9:277. 10.3389/fnagi.2017.0027728912710
65. Wang Y Ji X Leak RK Stem cell therapies in age-related neurodegenerative diseases and stroke Ageing Res Rev 2017 34 39 50 10.1016/j.arr.2016.11.002 27876573
Wang Y, Ji X, Leak RK et al (2017) Stem cell therapies in age-related neurodegenerative diseases and stroke. Ageing Res Rev 34:39–50. 10.1016/j.arr.2016.11.00227876573
66. Alessandrini M Preynat-Seauve O De Bruin K Pepper MS Stem cell therapy for neurological disorders S Afr Med J Suid-Afr Tydskr Vir Geneeskd 2019 109 70 77 10.7196/SAMJ.2019.v109i8b.14009
Alessandrini M, Preynat-Seauve O, De Bruin K, Pepper MS (2019) Stem cell therapy for neurological disorders. S Afr Med J Suid-Afr Tydskr Vir Geneeskd 109:70–77. 10.7196/SAMJ.2019.v109i8b.14009
67. Zhao L Liu J-W Shi H-Y Ma Y-M Neural stem cell therapy for brain disease World J Stem Cells 2021 13 1278 1292 10.4252/wjsc.v13.i9.1278 34630862
Zhao L, Liu J-W, Shi H-Y, Ma Y-M (2021) Neural stem cell therapy for brain disease. World J Stem Cells 13:1278–1292. 10.4252/wjsc.v13.i9.127834630862
68. Isaković J Šerer K Barišić B Mitrečić D Mesenchymal stem cell therapy for neurological disorders: the light or the dark side of the force? Front Bioeng Biotechnol 2023 11 1139359 10.3389/fbioe.2023.1139359 36926687
Isaković J, Šerer K, Barišić B, Mitrečić D (2023) Mesenchymal stem cell therapy for neurological disorders: the light or the dark side of the force? Front Bioeng Biotechnol 11:1139359. 10.3389/fbioe.2023.113935936926687
69. Kim I-K Park J-H Kim B Recent advances in stem cell therapy for neurodegenerative disease: three dimensional tracing and its emerging use World J Stem Cells 2021 13 1215 1230 10.4252/wjsc.v13.i9.1215 34630859
Kim I-K, Park J-H, Kim B et al (2021) Recent advances in stem cell therapy for neurodegenerative disease: three dimensional tracing and its emerging use. World J Stem Cells 13:1215–1230. 10.4252/wjsc.v13.i9.121534630859
70. Zhuang W-Z Lin Y-H Su L-J Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications J Biomed Sci 2021 28 28 10.1186/s12929-021-00725-7 33849537
Zhuang W-Z, Lin Y-H, Su L-J et al (2021) Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications. J Biomed Sci 28:28. 10.1186/s12929-021-00725-733849537
71. Kaminska A Radoszkiewicz K Rybkowska P Interaction of neural stem cells (NSCs) and mesenchymal stem cells (MSCs) as a promising approach in brain study and nerve regeneration Cells 2022 11 1464 10.3390/cells11091464 35563770
Kaminska A, Radoszkiewicz K, Rybkowska P et al (2022) Interaction of neural stem cells (NSCs) and mesenchymal stem cells (MSCs) as a promising approach in brain study and nerve regeneration. Cells 11:1464. 10.3390/cells1109146435563770
72. Pradhan AU Uwishema O Onyeaka H A review of stem cell therapy: an emerging treatment for dementia in Alzheimer’s and Parkinson’s disease Brain Behav 2022 12 e2740 10.1002/brb3.2740 35971625
Pradhan AU, Uwishema O, Onyeaka H et al (2022) A review of stem cell therapy: an emerging treatment for dementia in Alzheimer’s and Parkinson’s disease. Brain Behav 12:e2740. 10.1002/brb3.274035971625
73. Vidović M Rikalovic MG Alpha-synuclein aggregation pathway in Parkinson’s disease: current status and novel therapeutic approaches Cells 2022 11 1732 10.3390/cells11111732 35681426
Vidović M, Rikalovic MG (2022) Alpha-synuclein aggregation pathway in Parkinson’s disease: current status and novel therapeutic approaches. Cells 11:1732. 10.3390/cells1111173235681426
74. Neuroglia—an overview | ScienceDirect Topics. https://www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/neuroglia. Accessed 20 Jun 2024
75. Gonçalves GAR de Paiva RdMA Gene therapy: advances, challenges and perspectives Einstein Sao Paulo Braz 2017 15 369 375 10.1590/S1679-45082017RB4024
Gonçalves GAR, de Paiva RdMA (2017) Gene therapy: advances, challenges and perspectives. Einstein Sao Paulo Braz 15:369–375. 10.1590/S1679-45082017RB4024
76. Scheller EL Krebsbach PH Gene therapy J Dent Res 2009 88 585 596 10.1177/0022034509337480 19641145
Scheller EL, Krebsbach PH (2009) Gene therapy. J Dent Res 88:585–596. 10.1177/002203450933748019641145
77. Saffari M Moghimi HR Dass CR Barriers to liposomal gene delivery: from application site to the target Iran J Pharm Res IJPR 2016 15 3 17 28228799
Saffari M, Moghimi HR, Dass CR (2016) Barriers to liposomal gene delivery: from application site to the target. Iran J Pharm Res IJPR 15:3–1728228799
78. Raikwar SP Thangavel R Dubova I Neuro-immuno-gene- and genome-editing-therapy for Alzheimer’s disease: are we there yet? J Alzheimers Dis JAD 2018 65 321 344 10.3233/JAD-180422 30040732
Raikwar SP, Thangavel R, Dubova I et al (2018) Neuro-immuno-gene- and genome-editing-therapy for Alzheimer’s disease: are we there yet? J Alzheimers Dis JAD 65:321–344. 10.3233/JAD-18042230040732
79. Zhang J Wu X Qin C A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer’s disease Neurobiol Dis 2003 14 365 379 10.1016/j.nbd.2003.07.005 14678754
Zhang J, Wu X, Qin C et al (2003) A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer’s disease. Neurobiol Dis 14:365–379. 10.1016/j.nbd.2003.07.00514678754
80. Axelsen TM, Woldbye DPD gene therapy for Parkinson’s disease—an update. J Park Dis 8:195–215. 10.3233/JPD-181331
81. Sardi SP Cedarbaum JM Brundin P Targeted therapies for Parkinson’s disease: from genetics to the clinic Mov Disord 2018 33 684 696 10.1002/mds.27414 29704272
Sardi SP, Cedarbaum JM, Brundin P (2018) Targeted therapies for Parkinson’s disease: from genetics to the clinic. Mov Disord 33:684–696. 10.1002/mds.2741429704272
82. Yang H Zhang Q Zhang B Potential active marine peptides as anti-aging drugs or drug candidates Mar Drugs 2023 21 144 10.3390/md21030144 36976193
Yang H, Zhang Q, Zhang B et al (2023) Potential active marine peptides as anti-aging drugs or drug candidates. Mar Drugs 21:144. 10.3390/md2103014436976193
83. Shoshan-Barmatz V Anand U Nahon-Crystal E Adverse effects of metformin from diabetes to COVID-19, cancer, neurodegenerative diseases, and aging: is VDAC1 a common target? Front Physiol 2021 12 730048 10.3389/fphys.2021.730048 34671273
Shoshan-Barmatz V, Anand U, Nahon-Crystal E et al (2021) Adverse effects of metformin from diabetes to COVID-19, cancer, neurodegenerative diseases, and aging: is VDAC1 a common target? Front Physiol 12:730048. 10.3389/fphys.2021.73004834671273
84. Arriola Apelo SI Lamming DW Rapamycin: an InhibiTOR of aging emerges from the soil of Easter Island J Gerontol A Biol Sci Med Sci 2016 71 841 849 10.1093/gerona/glw090 27208895
Arriola Apelo SI, Lamming DW (2016) Rapamycin: an InhibiTOR of aging emerges from the soil of Easter Island. J Gerontol A Biol Sci Med Sci 71:841–849. 10.1093/gerona/glw09027208895
85. Shaito A Posadino AM Younes N Potential adverse effects of resveratrol: a literature review Int J Mol Sci 2020 21 2084 10.3390/ijms21062084 32197410
Shaito A, Posadino AM, Younes N et al (2020) Potential adverse effects of resveratrol: a literature review. Int J Mol Sci 21:2084. 10.3390/ijms2106208432197410
86. Du PY Gandhi A Bawa M Gromala J The ageing immune system as a potential target of senolytics Oxf Open Immunol 2023 4 iqad004 10.1093/oxfimm/iqad004 37255929
Du PY, Gandhi A, Bawa M, Gromala J (2023) The ageing immune system as a potential target of senolytics. Oxf Open Immunol 4:iqad004. 10.1093/oxfimm/iqad00437255929
87. Manenti S Orrico M Masciocchi S PD-1/PD-L axis in neuroinflammation: new insights Front Neurol 2022 10.3389/fneur.2022.877936 35756927
Manenti S, Orrico M, Masciocchi S et al (2022) PD-1/PD-L axis in neuroinflammation: new insights. Front Neurol. 10.3389/fneur.2022.87793635756927
88. Liu X Hogg GD DeNardo DG Rethinking immune checkpoint blockade: ‘beyond the T cell’ J Immunother Cancer 2021 9 e001460 10.1136/jitc-2020-001460 33468555
Liu X, Hogg GD, DeNardo DG (2021) Rethinking immune checkpoint blockade: ‘beyond the T cell.’ J Immunother Cancer 9:e001460. 10.1136/jitc-2020-00146033468555
89. Johnson DB Nebhan CA Moslehi JJ Balko JM Immune-checkpoint inhibitors: long-term implications of toxicity Nat Rev Clin Oncol 2022 19 254 267 10.1038/s41571-022-00600-w 35082367
Johnson DB, Nebhan CA, Moslehi JJ, Balko JM (2022) Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 19:254–267. 10.1038/s41571-022-00600-w35082367
90. Wu X Gu Z Chen Y Application of PD-1 blockade in cancer immunotherapy Comput Struct Biotechnol J 2019 17 661 674 10.1016/j.csbj.2019.03.006 31205619
Wu X, Gu Z, Chen Y et al (2019) Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J 17:661–674. 10.1016/j.csbj.2019.03.00631205619
91. Cai X Zhan H Ye Y Current progress and future perspectives of immune checkpoint in cancer and infectious diseases Front Genet 2021 10.3389/fgene.2021.785153 35154265
Cai X, Zhan H, Ye Y et al (2021) Current progress and future perspectives of immune checkpoint in cancer and infectious diseases. Front Genet. 10.3389/fgene.2021.78515335154265
92. Shiravand Y Khodadadi F Kashani SMA Immune checkpoint inhibitors in cancer therapy Curr Oncol 2022 29 3044 3060 10.3390/curroncol29050247 35621637
Shiravand Y, Khodadadi F, Kashani SMA et al (2022) Immune checkpoint inhibitors in cancer therapy. Curr Oncol 29:3044–3060. 10.3390/curroncol2905024735621637
93. Naimi A Mohammed RN Raji A Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons Cell Commun Signal 2022 20 44 10.1186/s12964-022-00854-y 35392976
Naimi A, Mohammed RN, Raji A et al (2022) Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal 20:44. 10.1186/s12964-022-00854-y35392976
94. Peng W Liu C Xu C PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines Cancer Res 2012 72 5209 5218 10.1158/0008-5472.CAN-12-1187 22915761
Peng W, Liu C, Xu C et al (2012) PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res 72:5209–5218. 10.1158/0008-5472.CAN-12-118722915761
95. Chang C-H Qiu J O’Sullivan D Metabolic competition in the tumor microenvironment is a driver of cancer progression Cell 2015 162 1229 1241 10.1016/j.cell.2015.08.016 26321679
Chang C-H, Qiu J, O’Sullivan D et al (2015) Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162:1229–1241. 10.1016/j.cell.2015.08.01626321679
96. Shergold AL Millar R Nibbs RJB Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade Pharmacol Res 2019 145 104258 10.1016/j.phrs.2019.104258 31063806
Shergold AL, Millar R, Nibbs RJB (2019) Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. Pharmacol Res 145:104258. 10.1016/j.phrs.2019.10425831063806
97. Aristizábal B, González Á (2013) Innate immune system. In: Autoimmunity: from bench to bedside [Internet]. El Rosario University Press
98. Alberts B, Johnson A, Lewis J, et al (2002) T cells and MHC proteins. In: Molecular biology of the cell. 4th edition. Garland Science
99. Informed Health.org (2023) Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006. In brief: The innate and adaptive immune systems. https://www.ncbi.nlm.nih.gov/books/NBK279396/
100. Wu L Wei Q Brzostek J Gascoigne NRJ Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells Cell Mol Immunol 2020 17 600 612 10.1038/s41423-020-0470-3 32451454
Wu L, Wei Q, Brzostek J, Gascoigne NRJ (2020) Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells. Cell Mol Immunol 17:600–612. 10.1038/s41423-020-0470-332451454
101. Muntjewerff EM Meesters LD van den Bogaart G Revelo NH Reverse signaling by MHC-I molecules in immune and non-immune cell types Front Immunol 2020 11 605958 10.3389/fimmu.2020.605958 33384693
Muntjewerff EM, Meesters LD, van den Bogaart G, Revelo NH (2020) Reverse signaling by MHC-I molecules in immune and non-immune cell types. Front Immunol 11:605958. 10.3389/fimmu.2020.60595833384693
102. Nagai S Azuma M Azuma M Yagita H The CD28–B7 family of co-signaling molecules Co-signal molecules in T cell activation: immune regulation in health and disease 2019 Singapore Springer 25 51
Nagai S, Azuma M (2019) The CD28–B7 family of co-signaling molecules. In: Azuma M, Yagita H (eds) Co-signal molecules in T cell activation: immune regulation in health and disease. Springer, Singapore, pp 25–51
103. Saeidi A Zandi K Cheok YY T-cell exhaustion in chronic infections: reversing the state of exhaustion and reinvigorating optimal protective immune responses Front Immunol 2018 9 2569 10.3389/fimmu.2018.02569 30473697
Saeidi A, Zandi K, Cheok YY et al (2018) T-cell exhaustion in chronic infections: reversing the state of exhaustion and reinvigorating optimal protective immune responses. Front Immunol 9:2569. 10.3389/fimmu.2018.0256930473697
104. Patsoukis N Bardhan K Chatterjee P PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation Nat Commun 2015 6 6692 10.1038/ncomms7692 25809635
Patsoukis N, Bardhan K, Chatterjee P et al (2015) PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun 6:6692. 10.1038/ncomms769225809635
105. Latchman YE Liang SC Wu Y PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells Proc Natl Acad Sci U S A 2004 101 10691 10696 10.1073/pnas.0307252101 15249675
Latchman YE, Liang SC, Wu Y et al (2004) PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A 101:10691–10696. 10.1073/pnas.030725210115249675
106. Probst HC McCoy K Okazaki T Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4 Nat Immunol 2005 6 280 286 10.1038/ni1165 15685176
Probst HC, McCoy K, Okazaki T et al (2005) Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 6:280–286. 10.1038/ni116515685176
107. Francisco LM Salinas VH Brown KE PD-L1 regulates the development, maintenance, and function of induced regulatory T cells J Exp Med 2009 206 3015 3029 10.1084/jem.20090847 20008522
Francisco LM, Salinas VH, Brown KE et al (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206:3015–3029. 10.1084/jem.2009084720008522
108. Sambucci M Gargano F De Rosa V FoxP3 isoforms and PD-1 expression by T regulatory cells in multiple sclerosis Sci Rep 2018 8 3674 10.1038/s41598-018-21861-5 29487369
Sambucci M, Gargano F, De Rosa V et al (2018) FoxP3 isoforms and PD-1 expression by T regulatory cells in multiple sclerosis. Sci Rep 8:3674. 10.1038/s41598-018-21861-529487369
109. Cai J Wang D Zhang G Guo X The role Of PD-1/PD-L1 Axis in treg development and function: implications for cancer immunotherapy OncoTargets Ther 2019 12 8437 8445 10.2147/OTT.S221340
Cai J, Wang D, Zhang G, Guo X (2019) The role Of PD-1/PD-L1 Axis in treg development and function: implications for cancer immunotherapy. OncoTargets Ther 12:8437–8445. 10.2147/OTT.S221340
110. Han Y Liu D Li L PD-1/PD-L1 pathway: current researches in cancer Am J Cancer Res 2020 10 727 742 32266087
Han Y, Liu D, Li L (2020) PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res 10:727–74232266087
111. Lin X Kang K Chen P Regulatory mechanisms of PD-1/PD-L1 in cancers Mol Cancer 2024 23 108 10.1186/s12943-024-02023-w 38762484
Lin X, Kang K, Chen P et al (2024) Regulatory mechanisms of PD-1/PD-L1 in cancers. Mol Cancer 23:108. 10.1186/s12943-024-02023-w38762484
112. Zhulai G Oleinik E Targeting regulatory T cells in anti-PD-1/PD-L1 cancer immunotherapy Scand J Immunol 2022 95 e13129 10.1111/sji.13129 34936125
Zhulai G, Oleinik E (2022) Targeting regulatory T cells in anti-PD-1/PD-L1 cancer immunotherapy. Scand J Immunol 95:e13129. 10.1111/sji.1312934936125
113. Zhang L Zhang M Xu J The role of the programmed cell death protein-1/programmed death-ligand 1 pathway, regulatory T cells and T helper 17 cells in tumor immunity: a narrative review Ann Transl Med 2020 8 1526 1526 10.21037/atm-20-6719 33313271
Zhang L, Zhang M, Xu J et al (2020) The role of the programmed cell death protein-1/programmed death-ligand 1 pathway, regulatory T cells and T helper 17 cells in tumor immunity: a narrative review. Ann Transl Med 8:1526–1526. 10.21037/atm-20-671933313271
114. Wang L Pino-Lagos K de Vries VC Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells Proc Natl Acad Sci 2008 105 9331 9336 10.1073/pnas.0710441105 18599457
Wang L, Pino-Lagos K, de Vries VC et al (2008) Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci 105:9331–9336. 10.1073/pnas.071044110518599457
115. Amarnath S Mangus CW Wang JCM The PDL1-PD1 axis converts human Th1 cells into regulatory T cells Sci Transl Med 2011 3 111ra120 10.1126/scitranslmed.3003130 22133721
Amarnath S, Mangus CW, Wang JCM et al (2011) The PDL1-PD1 axis converts human Th1 cells into regulatory T cells. Sci Transl Med 3:111ra120. 10.1126/scitranslmed.300313022133721
116. Stathopoulou C Gangaplara A Mallett G PD-1 inhibitory receptor downregulates asparaginyl endopeptidase and maintains Foxp3 transcription factor stability in induced regulatory T cells Immunity 2018 49 247 263.e7 10.1016/j.immuni.2018.05.006 30054205
Stathopoulou C, Gangaplara A, Mallett G et al (2018) PD-1 inhibitory receptor downregulates asparaginyl endopeptidase and maintains Foxp3 transcription factor stability in induced regulatory T cells. Immunity 49:247-263.e7. 10.1016/j.immuni.2018.05.00630054205
117. Latchman Y Wood CR Chernova T PD-L2 is a second ligand for PD-1 and inhibits T cell activation Nat Immunol 2001 2 261 268 10.1038/85330 11224527
Latchman Y, Wood CR, Chernova T et al (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2:261–268. 10.1038/8533011224527
118. Freeman GJ Long AJ Iwai Y Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 2000 192 1027 1034 10.1084/jem.192.7.1027 11015443
Freeman GJ, Long AJ, Iwai Y et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027–1034. 10.1084/jem.192.7.102711015443
119. Butte MJ Keir ME Phamduy TB Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses Immunity 2007 27 111 122 10.1016/j.immuni.2007.05.016 17629517
Butte MJ, Keir ME, Phamduy TB et al (2007) Programmed death-1 ligand 1 interacts specifically with the B7–1 costimulatory molecule to inhibit T cell responses. Immunity 27:111–122. 10.1016/j.immuni.2007.05.01617629517
120. Mair I Besusso D Saul L PD-1 expression is upregulated on adapted T cells in experimental autoimmune encephalomyelitis but is not required to maintain a hyporesponsive state Eur J Immunol 2019 49 112 120 10.1002/eji.201847868 30485411
Mair I, Besusso D, Saul L et al (2019) PD-1 expression is upregulated on adapted T cells in experimental autoimmune encephalomyelitis but is not required to maintain a hyporesponsive state. Eur J Immunol 49:112–120. 10.1002/eji.20184786830485411
121. Zinselmeyer BH Heydari S Sacristán C PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis J Exp Med 2013 210 757 774 10.1084/jem.20121416 23530125
Zinselmeyer BH, Heydari S, Sacristán C et al (2013) PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J Exp Med 210:757–774. 10.1084/jem.2012141623530125
122. Hu J He H Yang Z Programmed death ligand-1 on microglia regulates Th1 differentiation via nitric oxide in experimental autoimmune encephalomyelitis Neurosci Bull 2016 32 70 82 10.1007/s12264-015-0010-9 26769487
Hu J, He H, Yang Z et al (2016) Programmed death ligand-1 on microglia regulates Th1 differentiation via nitric oxide in experimental autoimmune encephalomyelitis. Neurosci Bull 32:70–82. 10.1007/s12264-015-0010-926769487
123. Norden DM Bethea JR Jiang J Impaired CD8 T cell antiviral immunity following acute spinal cord injury J Neuroinflamm 2018 15 149 10.1186/s12974-018-1191-8
Norden DM, Bethea JR, Jiang J (2018) Impaired CD8 T cell antiviral immunity following acute spinal cord injury. J Neuroinflamm 15:149. 10.1186/s12974-018-1191-8
124. Schachtele SJ Hu S Sheng WS Glial cells suppress postencephalitic CD8+ T lymphocytes through PD-L1 Glia 2014 62 1582 1594 10.1002/glia.22701 24890099
Schachtele SJ, Hu S, Sheng WS et al (2014) Glial cells suppress postencephalitic CD8+ T lymphocytes through PD-L1. Glia 62:1582–1594. 10.1002/glia.2270124890099
125. Lokensgard JR Schachtele SJ Mutnal MB Chronic reactive gliosis following regulatory T cell depletion during acute MCMV encephalitis Glia 2015 63 1982 1996 10.1002/glia.22868 26041050
Lokensgard JR, Schachtele SJ, Mutnal MB et al (2015) Chronic reactive gliosis following regulatory T cell depletion during acute MCMV encephalitis. Glia 63:1982–1996. 10.1002/glia.2286826041050
126. Zhang X-M Lund H Mia S Adoptive transfer of cytokine-induced immunomodulatory adult microglia attenuates experimental autoimmune encephalomyelitis in DBA/1 mice Glia 2014 62 804 817 10.1002/glia.22643 24677019
Zhang X-M, Lund H, Mia S et al (2014) Adoptive transfer of cytokine-induced immunomodulatory adult microglia attenuates experimental autoimmune encephalomyelitis in DBA/1 mice. Glia 62:804–817. 10.1002/glia.2264324677019
127. Chen Q Xu L Du T Enhanced expression of PD-L1 on microglia after surgical brain injury exerts self-protection from inflammation and promotes neurological repair Neurochem Res 2019 44 2470 2481 10.1007/s11064-019-02864-8 31482256
Chen Q, Xu L, Du T et al (2019) Enhanced expression of PD-L1 on microglia after surgical brain injury exerts self-protection from inflammation and promotes neurological repair. Neurochem Res 44:2470–2481. 10.1007/s11064-019-02864-831482256
128. Knopman DS Amieva H Petersen RC Alzheimer disease Nat Rev Dis Primer 2021 7 33 10.1038/s41572-021-00269-y
Knopman DS, Amieva H, Petersen RC et al (2021) Alzheimer disease. Nat Rev Dis Primer 7:33. 10.1038/s41572-021-00269-y
129. Kinney JW Bemiller SM Murtishaw AS Inflammation as a central mechanism in Alzheimer’s disease Alzheimers Dement N Y N 2018 4 575 590 10.1016/j.trci.2018.06.014
Kinney JW, Bemiller SM, Murtishaw AS et al (2018) Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement N Y N 4:575–590. 10.1016/j.trci.2018.06.014
130. Baruch K Deczkowska A Rosenzweig N PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer’s disease Nat Med 2016 22 135 137 10.1038/nm.4022 26779813
Baruch K, Deczkowska A, Rosenzweig N et al (2016) PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer’s disease. Nat Med 22:135–137. 10.1038/nm.402226779813
131. Latta-Mahieu M Elmer B Bretteville A Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-β burden in several amyloid transgenic mouse models Glia 2018 66 492 504 10.1002/glia.23260 29134678
Latta-Mahieu M, Elmer B, Bretteville A et al (2018) Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-β burden in several amyloid transgenic mouse models. Glia 66:492–504. 10.1002/glia.2326029134678
132. Ogawa C Liu Y-J Kobayashi KS Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy Curr Bioact Compd 2011 7 180 197 10.2174/157340711796817913 22180736
Ogawa C, Liu Y-J, Kobayashi KS (2011) Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy. Curr Bioact Compd 7:180–197. 10.2174/15734071179681791322180736
133. Traub S von Aulock S Hartung T Hermann C MDP and other muropeptides—direct and synergistic effects on the immune system J Endotoxin Res 2006 12 69 85 10.1179/096805106X89044 16690010
Traub S, von Aulock S, Hartung T, Hermann C (2006) MDP and other muropeptides—direct and synergistic effects on the immune system. J Endotoxin Res 12:69–85. 10.1179/096805106X8904416690010
134. Bashiri S Koirala P Toth I Skwarczynski M Carbohydrate immune adjuvants in subunit vaccines Pharmaceutics 2020 12 965 10.3390/pharmaceutics12100965 33066594
Bashiri S, Koirala P, Toth I, Skwarczynski M (2020) Carbohydrate immune adjuvants in subunit vaccines. Pharmaceutics 12:965. 10.3390/pharmaceutics1210096533066594
135. Piec P-A Pons V Préfontaine P Rivest S Muramyl dipeptide administration delays Alzheimer’s disease physiopathology via NOD2 receptors Cells 2022 11 2241 10.3390/cells11142241 35883683
Piec P-A, Pons V, Préfontaine P, Rivest S (2022) Muramyl dipeptide administration delays Alzheimer’s disease physiopathology via NOD2 receptors. Cells 11:2241. 10.3390/cells1114224135883683
136. Michaud J-P Bellavance M-A Préfontaine P Rivest S Real-time in vivo imaging reveals the ability of monocytes to clear vascular amyloid beta Cell Rep 2013 5 646 653 10.1016/j.celrep.2013.10.010 24210819
Michaud J-P, Bellavance M-A, Préfontaine P, Rivest S (2013) Real-time in vivo imaging reveals the ability of monocytes to clear vascular amyloid beta. Cell Rep 5:646–653. 10.1016/j.celrep.2013.10.01024210819
137. Ghareghani M Rivest S The synergistic potential of combining PD-1/PD-L1 immune checkpoint inhibitors with NOD2 agonists in Alzheimer’s disease treatment Int J Mol Sci 2023 24 10905 10.3390/ijms241310905 37446081
Ghareghani M, Rivest S (2023) The synergistic potential of combining PD-1/PD-L1 immune checkpoint inhibitors with NOD2 agonists in Alzheimer’s disease treatment. Int J Mol Sci 24:10905. 10.3390/ijms24131090537446081
138. Nimmo JT Kelly L Verma A Amyloid-β and α-synuclein immunotherapy: from experimental studies to clinical trials Front Neurosci 2021 15 733857 10.3389/fnins.2021.733857 34539340
Nimmo JT, Kelly L, Verma A et al (2021) Amyloid-β and α-synuclein immunotherapy: from experimental studies to clinical trials. Front Neurosci 15:733857. 10.3389/fnins.2021.73385734539340
139. Bayer V An overview of monoclonal antibodies Semin Oncol Nurs 2019 35 150927 10.1016/j.soncn.2019.08.006 31488319
Bayer V (2019) An overview of monoclonal antibodies. Semin Oncol Nurs 35:150927. 10.1016/j.soncn.2019.08.00631488319
140. Kumar M Thangavel C Becker RC Sadayappan S Monoclonal antibody-based immunotherapy and its role in the development of cardiac toxicity Cancers 2020 13 86 10.3390/cancers13010086 33396766
Kumar M, Thangavel C, Becker RC, Sadayappan S (2020) Monoclonal antibody-based immunotherapy and its role in the development of cardiac toxicity. Cancers 13:86. 10.3390/cancers1301008633396766
141. Mihăilă RG Monoclonal antibodies, bispecific antibodies and antibody-drug conjugates in oncohematology Recent Patents Anticancer Drug Discov 2020 15 272 292 10.2174/1574892815666200925120717
Mihăilă RG (2020) Monoclonal antibodies, bispecific antibodies and antibody-drug conjugates in oncohematology. Recent Patents Anticancer Drug Discov 15:272–292. 10.2174/1574892815666200925120717
142. Cummings J Osse AML Cammann D Anti-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease BioDrugs 2024 38 5 22 10.1007/s40259-023-00633-2 37955845
Cummings J, Osse AML, Cammann D et al (2024) Anti-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease. BioDrugs 38:5–22. 10.1007/s40259-023-00633-237955845
143. Gennaro P Taylor KI Judith A-C Trial of prasinezumab in early-stage Parkinson’s disease N Engl J Med 2022 387 421 432 10.1056/NEJMoa2202867 35921451
Gennaro P, Taylor KI, Judith A-C et al (2022) Trial of prasinezumab in early-stage Parkinson’s disease. N Engl J Med 387:421–432. 10.1056/NEJMoa220286735921451
144. BuddHaeberlein S Aisen PS Barkhof F Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease J Prev Alzheimers Dis 2022 9 197 210 10.14283/jpad.2022.30 35542991
BuddHaeberlein S, Aisen PS, Barkhof F et al (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis 9:197–210. 10.14283/jpad.2022.3035542991
145. Beshir SA Aadithsoorya AM Parveen A Aducanumab therapy to treat Alzheimer’s disease: a narrative review Int J Alzheimers Dis 2022 2022 9343514 10.1155/2022/9343514 35308835
Beshir SA, Aadithsoorya AM, Parveen A et al (2022) Aducanumab therapy to treat Alzheimer’s disease: a narrative review. Int J Alzheimers Dis 2022:9343514. 10.1155/2022/934351435308835
146. Biogen (2023) A randomized, open-label, parallel-arm study to assess the pharmacokinetic comparability of 2 fixed subcutaneous doses of aducanumab (BIIB037) with a single, weight-based intravenous dose in healthy volunteers. clinicaltrials.gov
147. Biogen (2021) A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aducanumab (BIIB037) in subjects with early Alzheimer’s Disease. clinicaltrials.gov
148. Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM® | Biogen. https://investors.biogen.com/news-releases/news-release-details/update-phase-4-envision-confirmatory-study-aduhelmr. Accessed 25 Jun 2024
149. Biogen (2024) A phase 3b/4 multicenter, randomized, double-blind, placebo-controlled, parallel-group study to verify the clinical benefit of aducanumab (BIIB037) in participants With Alzheimer’s disease. clinicaltrials.gov
150. Biogen (2024) Phase 3b open-label, multicenter, safety study of BIIB037 (Aducanumab) in subjects with Alzheimer’s disease who had previously participated in the Aducanumab studies 221AD103, 221AD301, 221AD302 and 221AD205. clinicaltrials.gov
151. van Dyck Christopher H Swanson CJ Paul A Lecanemab in early Alzheimer’s disease N Engl J Med 2023 388 9 21 10.1056/NEJMoa2212948 36449413
van Dyck Christopher H, Swanson CJ, Paul A et al (2023) Lecanemab in early Alzheimer’s disease. N Engl J Med 388:9–21. 10.1056/NEJMoa221294836449413
152. Eisai Inc. (2023) A placebo-controlled, double-blind, parallel-group, 18-month study with an open-label extension phase to confirm safety and efficacy of BAN2401 in subjects with early Alzheimer’s disease. clinicaltrials.gov
153. Bateman RJ Cummings J Schobel S Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease Alzheimers Res Ther 2022 10.1186/s13195-022-01110-8 36575454
Bateman RJ, Cummings J, Schobel S et al (2022) Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease. Alzheimers Res Ther. 10.1186/s13195-022-01110-836575454
154. Alawode DOT Heslegrave AJ Fox NC Zetterberg H Donanemab removes Alzheimer’s plaques: what is special about its target? Lancet Healthy Longev 2021 2 e395 e396 10.1016/S2666-7568(21)00144-6 36097986
Alawode DOT, Heslegrave AJ, Fox NC, Zetterberg H (2021) Donanemab removes Alzheimer’s plaques: what is special about its target? Lancet Healthy Longev 2:e395–e396. 10.1016/S2666-7568(21)00144-636097986
155. Chaurasiya A Katke S Panchal K Nirmal J Gupta U Kesharwani P Chapter 9—biologics for the management of dementia Nanomedicine-based approaches for the treatment of dementia 2023 Academic Press 193 234
Chaurasiya A, Katke S, Panchal K, Nirmal J (2023) Chapter 9—biologics for the management of dementia. In: Gupta U, Kesharwani P (eds) Nanomedicine-based approaches for the treatment of dementia. Academic Press, pp 193–234
156. Willis BA Sundell K Lachno DR Central pharmacodynamic activity of solanezumab in mild Alzheimer’s disease dementia Alzheimers Dement Transl Res Clin Interv 2018 4 652 660 10.1016/j.trci.2018.10.001
Willis BA, Sundell K, Lachno DR et al (2018) Central pharmacodynamic activity of solanezumab in mild Alzheimer’s disease dementia. Alzheimers Dement Transl Res Clin Interv 4:652–660. 10.1016/j.trci.2018.10.001
157. Ultsch M Li B Maurer T Structure of crenezumab complex with Aβ shows loss of β-Hairpin Sci Rep 2016 6 39374 10.1038/srep39374 27996029
Ultsch M, Li B, Maurer T et al (2016) Structure of crenezumab complex with Aβ shows loss of β-Hairpin. Sci Rep 6:39374. 10.1038/srep3937427996029
158. Esquer A Blanc F Collongues N immunotherapies targeting amyloid and tau protein in Alzheimer’s disease: should we move away from diseases and focus on biological targets? A systematic review and expert opinion Neurol Ther 2023 12 1883 1907 10.1007/s40120-023-00541-1 37812325
Esquer A, Blanc F, Collongues N (2023) immunotherapies targeting amyloid and tau protein in Alzheimer’s disease: should we move away from diseases and focus on biological targets? A systematic review and expert opinion. Neurol Ther 12:1883–1907. 10.1007/s40120-023-00541-137812325
159. Florian H Wang D Arnold SE Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study Brain J Neurol 2023 146 2275 2284 10.1093/brain/awad024
Florian H, Wang D, Arnold SE et al (2023) Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study. Brain J Neurol 146:2275–2284. 10.1093/brain/awad024
160. Younes K Sha SJ The most valuable player or the tombstone: is tau the correct target to treat Alzheimer’s disease? Brain 2023 146 2211 2213 10.1093/brain/awad151 37150887
Younes K, Sha SJ (2023) The most valuable player or the tombstone: is tau the correct target to treat Alzheimer’s disease? Brain 146:2211–2213. 10.1093/brain/awad15137150887
161. Lashuel HA Overk CR Oueslati A Masliah E The many faces of α-synuclein: from structure and toxicity to therapeutic target Nat Rev Neurosci 2013 14 38 48 10.1038/nrn3406 23254192
Lashuel HA, Overk CR, Oueslati A, Masliah E (2013) The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14:38–48. 10.1038/nrn340623254192
162. Masliah E Rockenstein E Veinbergs I dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders Science 2000 287 1265 1269 10.1126/science.287.5456.1265 10678833
Masliah E, Rockenstein E, Veinbergs I et al (2000) dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287:1265–1269. 10.1126/science.287.5456.126510678833
163. Galvin JE Lee VM-Y Trojanowski JQ Synucleinopathies: clinical and pathological implications Arch Neurol 2001 58 186 190 10.1001/archneur.58.2.186 11176955
Galvin JE, Lee VM-Y, Trojanowski JQ (2001) Synucleinopathies: clinical and pathological implications. Arch Neurol 58:186–190. 10.1001/archneur.58.2.18611176955
164. Overk CR Masliah E Pathogenesis of synaptic degeneration in Alzheimer’s disease and Lewy body disease Biochem Pharmacol 2014 88 508 516 10.1016/j.bcp.2014.01.015 24462903
Overk CR, Masliah E (2014) Pathogenesis of synaptic degeneration in Alzheimer’s disease and Lewy body disease. Biochem Pharmacol 88:508–516. 10.1016/j.bcp.2014.01.01524462903
165. Lee S-J Desplats P Sigurdson C Cell-to-cell transmission of non-prion protein aggregates Nat Rev Neurol 2010 6 702 706 10.1038/nrneurol.2010.145 21045796
Lee S-J, Desplats P, Sigurdson C et al (2010) Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol 6:702–706. 10.1038/nrneurol.2010.14521045796
166. Brettschneider J Del Tredici K Lee VM-Y Trojanowski JQ Spreading of pathology in neurodegenerative diseases: a focus on human studies Nat Rev Neurosci 2015 16 109 120 10.1038/nrn3887 25588378
Brettschneider J, Del Tredici K, Lee VM-Y, Trojanowski JQ (2015) Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci 16:109–120. 10.1038/nrn388725588378
167. Masliah E Rockenstein E Adame A Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease Neuron 2005 46 857 868 10.1016/j.neuron.2005.05.010 15953415
Masliah E, Rockenstein E, Adame A et al (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease. Neuron 46:857–868. 10.1016/j.neuron.2005.05.01015953415
168. Henderson MX, Covell DJ, Chung CH-Y, Pitkin RM, Sandler RM, Decker SC, Riddle DM, Zhang B, Gathagan RJ, James MJ, Trojanowski JQ, Brunden KR, Lee VMY, Luk KC (2020) Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson’s disease. Neurobiol Dis 136:104712. 10.1016/j.nbd.2019.104712
169. Tran HT Chung CH-Y Iba M Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration Cell Rep 2014 7 2054 2065 10.1016/j.celrep.2014.05.033 24931606
Tran HT, Chung CH-Y, Iba M et al (2014) Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration. Cell Rep 7:2054–2065. 10.1016/j.celrep.2014.05.03324931606
170. Masliah E Rockenstein E Mante M Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease PLoS ONE 2011 6 e19338 10.1371/journal.pone.0019338 21559417
Masliah E, Rockenstein E, Mante M et al (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE 6:e19338. 10.1371/journal.pone.001933821559417
171. Spencer B Valera E Rockenstein E Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy Acta Neuropathol Commun 2017 5 7 10.1186/s40478-016-0410-8 28086964
Spencer B, Valera E, Rockenstein E et al (2017) Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy. Acta Neuropathol Commun 5:7. 10.1186/s40478-016-0410-828086964
172. Bird RE Hardman KD Jacobson JW Single-chain antigen-binding proteins Science 1988 242 423 426 10.1126/science.3140379 3140379
Bird RE, Hardman KD, Jacobson JW et al (1988) Single-chain antigen-binding proteins. Science 242:423–426. 10.1126/science.31403793140379
173. Marschall ALJ Dübel S Antibodies inside of a cell can change its outside: can intrabodies provide a new therapeutic paradigm? Comput Struct Biotechnol J 2016 14 304 308 10.1016/j.csbj.2016.07.003 27570612
Marschall ALJ, Dübel S (2016) Antibodies inside of a cell can change its outside: can intrabodies provide a new therapeutic paradigm? Comput Struct Biotechnol J 14:304–308. 10.1016/j.csbj.2016.07.00327570612
174. Menon S Armstrong S Hamzeh A Alpha-synuclein targeting therapeutics for Parkinson’s disease and related synucleinopathies Front Neurol 2022 13 852003 10.3389/fneur.2022.852003 35614915
Menon S, Armstrong S, Hamzeh A et al (2022) Alpha-synuclein targeting therapeutics for Parkinson’s disease and related synucleinopathies. Front Neurol 13:852003. 10.3389/fneur.2022.85200335614915
175. Brundin P Dave KD Kordower JH Therapeutic approaches to target alpha-synuclein pathology Exp Neurol 2017 298 225 235 10.1016/j.expneurol.2017.10.003 28987463
Brundin P, Dave KD, Kordower JH (2017) Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol 298:225–235. 10.1016/j.expneurol.2017.10.00328987463
176. Knecht L Folke J Dodel R Alpha-synuclein immunization strategies for synucleinopathies in clinical studies: a biological perspective Neurother J Am Soc Exp Neurother 2022 19 1489 1502 10.1007/s13311-022-01288-7
Knecht L, Folke J, Dodel R et al (2022) Alpha-synuclein immunization strategies for synucleinopathies in clinical studies: a biological perspective. Neurother J Am Soc Exp Neurother 19:1489–1502. 10.1007/s13311-022-01288-7
177. Chatterjee D Kordower JH Immunotherapy in Parkinson’s disease: current status and future directions Neurobiol Dis 2019 132 104587 10.1016/j.nbd.2019.104587 31454546
Chatterjee D, Kordower JH (2019) Immunotherapy in Parkinson’s disease: current status and future directions. Neurobiol Dis 132:104587. 10.1016/j.nbd.2019.10458731454546
178. Fernández-Valle T Gabilondo I Gómez-Esteban JC New therapeutic approaches to target alpha-synuclein in Parkinson’s disease: the role of immunotherapy Int Rev Neurobiol 2019 146 281 295 10.1016/bs.irn.2019.06.014 31349931
Fernández-Valle T, Gabilondo I, Gómez-Esteban JC (2019) New therapeutic approaches to target alpha-synuclein in Parkinson’s disease: the role of immunotherapy. Int Rev Neurobiol 146:281–295. 10.1016/bs.irn.2019.06.01431349931
179. Nimmo JT Verma A Dodart J-C Correction: novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy Alzheimers Res Ther 2023 15 18 10.1186/s13195-022-01156-8 36681823
Nimmo JT, Verma A, Dodart J-C et al (2023) Correction: novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy. Alzheimers Res Ther 15:18. 10.1186/s13195-022-01156-836681823
180. Mandler M Valera E Rockenstein E Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy Mol Neurodegener 2015 10 10 10.1186/s13024-015-0008-9 25886309
Mandler M, Valera E, Rockenstein E et al (2015) Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener 10:10. 10.1186/s13024-015-0008-925886309
181. Games D Valera E Spencer B Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson’s disease-like models J Neurosci 2014 34 9441 9454 10.1523/JNEUROSCI.5314-13.2014 25009275
Games D, Valera E, Spencer B et al (2014) Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson’s disease-like models. J Neurosci 34:9441–9454. 10.1523/JNEUROSCI.5314-13.201425009275
182. Bae E-J Lee H-J Rockenstein E Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission J Neurosci 2012 32 13454 13469 10.1523/JNEUROSCI.1292-12.2012 23015436
Bae E-J, Lee H-J, Rockenstein E et al (2012) Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 32:13454–13469. 10.1523/JNEUROSCI.1292-12.201223015436
183. Nimmo JT Smith H Wang CY Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut Acta Neuropathol (Berl) 2022 143 55 73 10.1007/s00401-021-02381-5 34741635
Nimmo JT, Smith H, Wang CY et al (2022) Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut. Acta Neuropathol (Berl) 143:55–73. 10.1007/s00401-021-02381-534741635
184. Nimmo JT Verma A Dodart J-C Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy Alzheimers Res Ther 2020 12 159 10.1186/s13195-020-00727-x 33256825
Nimmo JT, Verma A, Dodart J-C et al (2020) Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy. Alzheimers Res Ther 12:159. 10.1186/s13195-020-00727-x33256825
185. Rabl R Breitschaedel C Flunkert S Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice BMC Neurosci 2017 18 22 10.1186/s12868-017-0341-8 28143405
Rabl R, Breitschaedel C, Flunkert S et al (2017) Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice. BMC Neurosci 18:22. 10.1186/s12868-017-0341-828143405
186. Schofield DJ Irving L Calo L Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo Neurobiol Dis 2019 132 104582 10.1016/j.nbd.2019.104582 31445162
Schofield DJ, Irving L, Calo L et al (2019) Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo. Neurobiol Dis 132:104582. 10.1016/j.nbd.2019.10458231445162
187. Wang Q Delva L Weinreb PH Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration Fluids Barriers CNS 2018 15 10 10.1186/s12987-018-0093-6 29558954
Wang Q, Delva L, Weinreb PH et al (2018) Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration. Fluids Barriers CNS 15:10. 10.1186/s12987-018-0093-629558954
188. Weihofen A Liu Y Arndt JW Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson’s disease models Neurobiol Dis 2019 124 276 288 10.1016/j.nbd.2018.10.016 30381260
Weihofen A, Liu Y, Arndt JW et al (2019) Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson’s disease models. Neurobiol Dis 124:276–288. 10.1016/j.nbd.2018.10.01630381260
189. Fjord-Larsen L Thougaard A Wegener KM Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies MAbs 2021 13 1994690 10.1080/19420862.2021.1994690 34709986
Fjord-Larsen L, Thougaard A, Wegener KM et al (2021) Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies. MAbs 13:1994690. 10.1080/19420862.2021.199469034709986
190. Shahaduzzaman M Nash K Hudson C Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson’s disease PLoS ONE 2015 10 e0116841 10.1371/journal.pone.0116841 25658425
Shahaduzzaman M, Nash K, Hudson C et al (2015) Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson’s disease. PLoS ONE 10:e0116841. 10.1371/journal.pone.011684125658425
191. Jankovic J Goodman I Safirstein B Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-α-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial JAMA Neurol 2018 75 1206 1214 10.1001/jamaneurol.2018.1487 29913017
Jankovic J, Goodman I, Safirstein B et al (2018) Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-α-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurol 75:1206–1214. 10.1001/jamaneurol.2018.148729913017
192. Pagano G Boess FG Taylor KI A phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease (PASADENA): rationale, design, and baseline data Front Neurol 2021 12 705407 10.3389/fneur.2021.705407 34659081
Pagano G, Boess FG, Taylor KI et al (2021) A phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease (PASADENA): rationale, design, and baseline data. Front Neurol 12:705407. 10.3389/fneur.2021.70540734659081
193. Pagano G Taylor KI Anzures-Cabrera J Trial of prasinezumab in early-stage Parkinson’s disease N Engl J Med 2022 387 421 432 10.1056/NEJMoa2202867 35921451
Pagano G, Taylor KI, Anzures-Cabrera J et al (2022) Trial of prasinezumab in early-stage Parkinson’s disease. N Engl J Med 387:421–432. 10.1056/NEJMoa220286735921451
194. Kuchimanchi M Monine M Kandadi Muralidharan K Phase II dose selection for alpha synuclein-targeting antibody cinpanemab (BIIB054) based on target protein binding levels in the brain CPT Pharmacometr Syst Pharmacol 2020 9 515 522 10.1002/psp4.12538
Kuchimanchi M, Monine M, Kandadi Muralidharan K et al (2020) Phase II dose selection for alpha synuclein-targeting antibody cinpanemab (BIIB054) based on target protein binding levels in the brain. CPT Pharmacometr Syst Pharmacol 9:515–522. 10.1002/psp4.12538
195. Volc D Poewe W Kutzelnigg A Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson’s disease: a randomised, single-blinded, phase 1 trial Lancet Neurol 2020 19 591 600 10.1016/S1474-4422(20)30136-8 32562684
Volc D, Poewe W, Kutzelnigg A et al (2020) Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson’s disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol 19:591–600. 10.1016/S1474-4422(20)30136-832562684
196. Poewe W Volc D Seppi K Safety and tolerability of active immunotherapy targeting α-synuclein with PD03A in patients with early Parkinson’s disease: a randomized, placebo-controlled, phase 1 study J Parkinson Dis 2021 11 1079 1089 10.3233/JPD-212594
Poewe W, Volc D, Seppi K et al (2021) Safety and tolerability of active immunotherapy targeting α-synuclein with PD03A in patients with early Parkinson’s disease: a randomized, placebo-controlled, phase 1 study. J Parkinson Dis 11:1079–1089. 10.3233/JPD-212594
197. Yu HJ Thijssen E van Brummelen E A randomized first-in-human study with UB-312, a UBITh® α-synuclein peptide vaccine Mov Disord 2022 37 1416 1424 10.1002/mds.29016 35426173
Yu HJ, Thijssen E, van Brummelen E et al (2022) A randomized first-in-human study with UB-312, a UBITh® α-synuclein peptide vaccine. Mov Disord 37:1416–1424. 10.1002/mds.2901635426173
198. Pugazhenthi S Qin L Reddy PH Common neurodegenerative pathways in obesity, diabetes, and Alzheimer’s disease Biochim Biophys Acta Mol Basis Dis 2017 1863 1037 1045 10.1016/j.bbadis.2016.04.017 27156888
Pugazhenthi S, Qin L, Reddy PH (2017) Common neurodegenerative pathways in obesity, diabetes, and Alzheimer’s disease. Biochim Biophys Acta Mol Basis Dis 1863:1037–1045. 10.1016/j.bbadis.2016.04.01727156888
199. Immune checkpoint inhibitors and their side effects. https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html. Accessed 18 Sep 2023
200. Martins F Sofiya L Sykiotis GP Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance Nat Rev Clin Oncol 2019 16 563 580 10.1038/s41571-019-0218-0 31092901
Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563–580. 10.1038/s41571-019-0218-031092901
201. Wu C-T Chu C-I Wang F-Y A change of PD-1/PD-L1 expression on peripheral T cell subsets correlates with the different stages of Alzheimer’s Disease Cell Biosci 2022 12 162 10.1186/s13578-022-00897-1 36180897
Wu C-T, Chu C-I, Wang F-Y et al (2022) A change of PD-1/PD-L1 expression on peripheral T cell subsets correlates with the different stages of Alzheimer’s Disease. Cell Biosci 12:162. 10.1186/s13578-022-00897-136180897
202. Wagner M Jasek M Karabon L Immune checkpoint molecules-inherited variations as markers for cancer risk Front Immunol 2020 11 606721 10.3389/fimmu.2020.606721 33519815
Wagner M, Jasek M, Karabon L (2020) Immune checkpoint molecules-inherited variations as markers for cancer risk. Front Immunol 11:606721. 10.3389/fimmu.2020.60672133519815
203. Can cancer immunotherapy principles be applied to neurodegenerative diseases? In: RD Syst. https://www.rndsystems.com/blog/can-cancer-immunotherapy-principles-be-applied-neurodegenerative-diseases. Accessed 18 Sep 2023
204. Wang SJ Dougan SK Dougan M Immune mechanisms of toxicity from checkpoint inhibitors Trends Cancer 2023 9 543 553 10.1016/j.trecan.2023.04.002 37117135
Wang SJ, Dougan SK, Dougan M (2023) Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer 9:543–553. 10.1016/j.trecan.2023.04.00237117135
205. Lecis D Sangaletti S Colombo MP Chiodoni C Immune checkpoint ligand reverse signaling: looking back to go forward in cancer therapy Cancers 2019 11 624 10.3390/cancers11050624 31060225
Lecis D, Sangaletti S, Colombo MP, Chiodoni C (2019) Immune checkpoint ligand reverse signaling: looking back to go forward in cancer therapy. Cancers 11:624. 10.3390/cancers1105062431060225
206. Huang Y-T Chen Y-P Lin W-C Immune checkpoint inhibitor-induced myasthenia gravis Front Neurol 2020 11 634 10.3389/fneur.2020.00634 32765397
Huang Y-T, Chen Y-P, Lin W-C et al (2020) Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol 11:634. 10.3389/fneur.2020.0063432765397
207. Puzanov I Diab A Abdallah K Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group J Immunother Cancer 2017 5 95 10.1186/s40425-017-0300-z 29162153
Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5:95. 10.1186/s40425-017-0300-z29162153
208. Schwartz M Arad M Ben-Yehuda H Potential immunotherapy for Alzheimer disease and age-related dementia Dialogues Clin Neurosci 2019 21 21 25 10.31887/DCNS.2019.21.1/mschwartz 31607777
Schwartz M, Arad M, Ben-Yehuda H (2019) Potential immunotherapy for Alzheimer disease and age-related dementia. Dialogues Clin Neurosci 21:21–2531607777
209. Stuby J Herren T Schwegler Naumburger G Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature Swiss Med Wkly 2020 150 w20377 10.4414/smw.2020.20377 33232507
Stuby J, Herren T, Schwegler Naumburger G et al (2020) Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature. Swiss Med Wkly 150:w20377. 10.4414/smw.2020.2037733232507
210. Haanen JBAG Carbonnel F Robert C Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2017 28 iv119 iv142 10.1093/annonc/mdx225 28881921
Haanen JBAG, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119–iv142. 10.1093/annonc/mdx22528881921
211. Zhu J Li Y Myasthenia gravis exacerbation associated with pembrolizumab Muscle Nerve 2016 54 506 507 10.1002/mus.25055 26802533
Zhu J, Li Y (2016) Myasthenia gravis exacerbation associated with pembrolizumab. Muscle Nerve 54:506–507. 10.1002/mus.2505526802533
212. Rhee JY Torun N Neilan TG Guidon AC Consider myocarditis when patients treated with immune checkpoint inhibitors present with ocular symptoms Oncologist 2022 27 e402 e405 10.1093/oncolo/oyac033 35348772
Rhee JY, Torun N, Neilan TG, Guidon AC (2022) Consider myocarditis when patients treated with immune checkpoint inhibitors present with ocular symptoms. Oncologist 27:e402–e405. 10.1093/oncolo/oyac03335348772
213. Inno A Tarantini L Parrini I Cardiovascular effects of immune checkpoint inhibitors: more than just myocarditis Curr Oncol Rep 2023 25 743 751 10.1007/s11912-023-01411-7 37017825
Inno A, Tarantini L, Parrini I et al (2023) Cardiovascular effects of immune checkpoint inhibitors: more than just myocarditis. Curr Oncol Rep 25:743–751. 10.1007/s11912-023-01411-737017825
214. Wang DY Salem J-E Cohen JV Fatal toxic effects associated with immune checkpoint inhibitors JAMA Oncol 2018 4 1721 1728 10.1001/jamaoncol.2018.3923 30242316
Wang DY, Salem J-E, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors. JAMA Oncol 4:1721–1728. 10.1001/jamaoncol.2018.392330242316
215. Zhang L Reynolds KL Lyon AR The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity JACC CardioOncol 2021 3 35 47 10.1016/j.jaccao.2020.11.012 33842895
Zhang L, Reynolds KL, Lyon AR et al (2021) The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity. JACC CardioOncol 3:35–47. 10.1016/j.jaccao.2020.11.01233842895
216. Rubio-Infante N Ramírez-Flores YA Castillo EC Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis Eur J Heart Fail 2021 23 1739 1747 10.1002/ejhf.2289 34196077
Rubio-Infante N, Ramírez-Flores YA, Castillo EC et al (2021) Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail 23:1739–1747. 10.1002/ejhf.228934196077
217. Ma Q Shilkrut M Zhao Z Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data BMC Cancer 2018 18 145 10.1186/s12885-018-4051-0 29409500
Ma Q, Shilkrut M, Zhao Z et al (2018) Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data. BMC Cancer 18:145. 10.1186/s12885-018-4051-029409500
218. Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options | Lung Cancer | JAMA Oncology | JAMA Network. https://jamanetwork.com/journals/jamaoncology/article-abstract/2526994. Accessed 18 Sep 2023
219. Thavendiranathan P Sacher A A new risk factor for cardiovascular events in patients receiving immune checkpoint inhibitor therapy? JACC CardioOncol 2022 4 670 672 10.1016/j.jaccao.2022.11.010 36636452
Thavendiranathan P, Sacher A (2022) A new risk factor for cardiovascular events in patients receiving immune checkpoint inhibitor therapy? JACC CardioOncol 4:670–672. 10.1016/j.jaccao.2022.11.01036636452
220. Song Y Fu Y Xie Q Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment Front Immunol 2020 11 1956 10.3389/fimmu.2020.01956 32983126
Song Y, Fu Y, Xie Q et al (2020) Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment. Front Immunol 11:1956. 10.3389/fimmu.2020.0195632983126
221. Park Y-J Kuen D-S Chung Y Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance Exp Mol Med 2018 50 1 13 10.1038/s12276-018-0130-1 30523262
Park Y-J, Kuen D-S, Chung Y (2018) Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. Exp Mol Med 50:1–13. 10.1038/s12276-018-0130-130523262
222. Yi M Jiao D Qin S Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment Mol Cancer 2019 18 60 10.1186/s12943-019-0974-6 30925919
Yi M, Jiao D, Qin S et al (2019) Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer 18:60. 10.1186/s12943-019-0974-630925919
223. Jenkins RW Barbie DA Flaherty KT Mechanisms of resistance to immune checkpoint inhibitors Br J Cancer 2018 118 9 16 10.1038/bjc.2017.434 29319049
Jenkins RW, Barbie DA, Flaherty KT (2018) Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer 118:9–16. 10.1038/bjc.2017.43429319049
224. Salik B Smyth MJ Nakamura K Targeting immune checkpoints in hematological malignancies J Hematol OncolJ Hematol Oncol 2020 13 111 10.1186/s13045-020-00947-6 32787882
Salik B, Smyth MJ, Nakamura K (2020) Targeting immune checkpoints in hematological malignancies. J Hematol Oncol 13:111. 10.1186/s13045-020-00947-632787882
225. Dobosz P Stępień M Golke A Dzieciątkowski T Challenges of the immunotherapy: perspectives and limitations of the immune checkpoint inhibitor treatment Int J Mol Sci 2022 23 2847 10.3390/ijms23052847 35269988
Dobosz P, Stępień M, Golke A, Dzieciątkowski T (2022) Challenges of the immunotherapy: perspectives and limitations of the immune checkpoint inhibitor treatment. Int J Mol Sci 23:2847. 10.3390/ijms2305284735269988
226. Association of immune checkpoint inhibitors with neurologic adverse events: a systematic review and meta-analysis | Oncology | JAMA Network Open | JAMA Network. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2791294#zoi220244r2. Accessed 18 Sep 2023
227. Spain L Tippu Z Larkin JM How we treat neurological toxicity from immune checkpoint inhibitors ESMO Open 2019 4 e000540 10.1136/esmoopen-2019-000540 31423344
Spain L, Tippu Z, Larkin JM et al (2019) How we treat neurological toxicity from immune checkpoint inhibitors. ESMO Open 4:e000540. 10.1136/esmoopen-2019-00054031423344
228. Lamptey RNL Chaulagain B Trivedi R A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics Int J Mol Sci 2022 23 1851 10.3390/ijms23031851 35163773
Lamptey RNL, Chaulagain B, Trivedi R et al (2022) A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci 23:1851. 10.3390/ijms2303185135163773
229. Kumar A, Sidhu J, Lui F, Tsao JW (2024) Alzheimer Disease. In: StatPearls. StatPearls Publishing, Treasure Island (FL)
230. Kouli A Torsney KM Kuan W-L Stoker TB Greenland JC Parkinson’s disease: etiology, neuropathology, and pathogenesis Parkinson’s disease: pathogenesis and clinical aspects 2018 Brisbane (AU) Codon Publications
Kouli A, Torsney KM, Kuan W-L (2018) Parkinson’s disease: etiology, neuropathology, and pathogenesis. In: Stoker TB, Greenland JC (eds) Parkinson’s disease: pathogenesis and clinical aspects. Codon Publications, Brisbane (AU)
231. Karvelas N Bennett S Politis G Advances in stem cell therapy in Alzheimer’s disease: a comprehensive clinical trial review Stem Cell Investig 2022 9 2 10.21037/sci-2021-063 35280344
Karvelas N, Bennett S, Politis G et al (2022) Advances in stem cell therapy in Alzheimer’s disease: a comprehensive clinical trial review. Stem Cell Investig 9:2. 10.21037/sci-2021-06335280344
232. Thirabanjasak D Tantiwongse K Thorner PS Angiomyeloproliferative lesions following autologous stem cell therapy J Am Soc Nephrol JASN 2010 21 1218 1222 10.1681/ASN.2009111156 20558536
Thirabanjasak D, Tantiwongse K, Thorner PS (2010) Angiomyeloproliferative lesions following autologous stem cell therapy. J Am Soc Nephrol JASN 21:1218–1222. 10.1681/ASN.200911115620558536
233. Amariglio N Hirshberg A Scheithauer BW Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient PLoS Med 2009 6 e1000029 10.1371/journal.pmed.1000029 19226183
Amariglio N, Hirshberg A, Scheithauer BW et al (2009) Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 6:e1000029. 10.1371/journal.pmed.100002919226183
234. Fazel SS Angoulvant D Butany J Mesenchymal stem cells engineered to overexpress stem cell factor improve cardiac function but have malignant potential J Thorac Cardiovasc Surg 2008 136 1388 1389 10.1016/j.jtcvs.2007.11.068 19026843
Fazel SS, Angoulvant D, Butany J et al (2008) Mesenchymal stem cells engineered to overexpress stem cell factor improve cardiac function but have malignant potential. J Thorac Cardiovasc Surg 136:1388–1389. 10.1016/j.jtcvs.2007.11.06819026843
235. Kastanenka KV Bussiere T Shakerdge N Immunotherapy with aducanumab restores calcium homeostasis in Tg2576 mice J Neurosci 2016 36 12549 12558 10.1523/JNEUROSCI.2080-16.2016 27810931
Kastanenka KV, Bussiere T, Shakerdge N et al (2016) Immunotherapy with aducanumab restores calcium homeostasis in Tg2576 mice. J Neurosci 36:12549–12558. 10.1523/JNEUROSCI.2080-16.201627810931
236. Sevigny J Chiao P Bussière T The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease Nature 2016 537 50 56 10.1038/nature19323 27582220
Sevigny J, Chiao P, Bussière T et al (2016) The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 537:50–56. 10.1038/nature1932327582220
237. Mo J-J Li J-Y Yang Z Efficacy and safety of anti-amyloid-β immunotherapy for Alzheimer’s disease: a systematic review and network meta-analysis Ann Clin Transl Neurol 2017 4 931 942 10.1002/acn3.469 29296624
Mo J-J, Li J-Y, Yang Z et al (2017) Efficacy and safety of anti-amyloid-β immunotherapy for Alzheimer’s disease: a systematic review and network meta-analysis. Ann Clin Transl Neurol 4:931–942. 10.1002/acn3.46929296624
238. Haddad HW Malone GW Comardelle NJ Aducanumab, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s disease: a comprehensive review Health Psychol Res 2022 10 31925 35928986
Haddad HW, Malone GW, Comardelle NJ et al (2022) Aducanumab, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s disease: a comprehensive review. Health Psychol Res 10:3192535928986
239. Ferrero J Williams L Stella H First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer’s disease Alzheimers Dement N Y N 2016 2 169 176 10.1016/j.trci.2016.06.002
Ferrero J, Williams L, Stella H et al (2016) First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer’s disease. Alzheimers Dement N Y N 2:169–176. 10.1016/j.trci.2016.06.002
240. Tian Hui Kwan A Arfaie S Therriault J Lessons learnt from the second generation of anti-amyloid monoclonal antibodies clinical trials Dement Geriatr Cogn Disord 2020 49 334 348 10.1159/000511506 33321511
Tian Hui Kwan A, Arfaie S, Therriault J et al (2020) Lessons learnt from the second generation of anti-amyloid monoclonal antibodies clinical trials. Dement Geriatr Cogn Disord 49:334–348. 10.1159/00051150633321511
241. Kuller LH Lopez OL Engage and emerge: truth and consequences? Alzheimers Dement J Alzheimers Assoc 2021 17 692 695 10.1002/alz.12286
Kuller LH, Lopez OL (2021) Engage and emerge: truth and consequences? Alzheimers Dement J Alzheimers Assoc 17:692–695. 10.1002/alz.12286
242. Alexander GC Emerson S Kesselheim AS Evaluation of Aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility JAMA 2021 325 1717 1718 10.1001/jama.2021.3854 33783469
Alexander GC, Emerson S, Kesselheim AS (2021) Evaluation of Aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA 325:1717–1718. 10.1001/jama.2021.385433783469
243. Andrews JS Desai U Kirson NY Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer’s disease clinical trials Alzheimers Dement N Y N 2019 5 354 363 10.1016/j.trci.2019.06.005
Andrews JS, Desai U, Kirson NY et al (2019) Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer’s disease clinical trials. Alzheimers Dement N Y N 5:354–363. 10.1016/j.trci.2019.06.005
244. Cummings J Aisen P Lemere C Aducanumab produced a clinically meaningful benefit in association with amyloid lowering Alzheimers Res Ther 2021 13 98 10.1186/s13195-021-00838-z 33971962
Cummings J, Aisen P, Lemere C et al (2021) Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res Ther 13:98. 10.1186/s13195-021-00838-z33971962
245. Edvardsson D Winblad B Sandman PO Person-centred care of people with severe Alzheimer’s disease: current status and ways forward Lancet Neurol 2008 7 362 367 10.1016/S1474-4422(08)70063-2 18339351
Edvardsson D, Winblad B, Sandman PO (2008) Person-centred care of people with severe Alzheimer’s disease: current status and ways forward. Lancet Neurol 7:362–367. 10.1016/S1474-4422(08)70063-218339351
246. Qiao Y Chi Y Zhang Q Ma Y Safety and efficacy of lecanemab for Alzheimer’s disease: a systematic review and meta-analysis of randomized clinical trials Front Aging Neurosci 2023 15 1169499 10.3389/fnagi.2023.1169499 37213538
Qiao Y, Chi Y, Zhang Q, Ma Y (2023) Safety and efficacy of lecanemab for Alzheimer’s disease: a systematic review and meta-analysis of randomized clinical trials. Front Aging Neurosci 15:1169499. 10.3389/fnagi.2023.116949937213538
247. Brys M Fanning L Hung S Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054 Mov Disord 2019 34 1154 1163 10.1002/mds.27738 31211448
Brys M, Fanning L, Hung S et al (2019) Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054. Mov Disord 34:1154–1163. 10.1002/mds.2773831211448
